Clinical Practice Guideline (Update): Adult Sinusitis

Richard M. Rosenfeld, MD, MPH1, Jay F. Piccirillo, MD2, Sujana S. Chandrasekhar, MD3, Itzhak Brook, MD, MSc4, Kaparaboyna Ashok Kumar, MD, FRCS5, Maggie Kramper, RN, FNP6, Richard R. Orlandi, MD7, James N. Palmer, MD8, Zara M. Patel, MD9, Anju Peters, MD10, Sandra A. Walsh11, and Maureen D. Corrigan12

Abstract

Objective. This update of a 2007 guideline from the American Academy of Otolaryngology—Head and Neck Surgery Foundation provides evidence-based recommendations to manage adult rhinosinusitis, defined as symptomatic inflammation of the paranasal sinuses and nasal cavity. Changes from the prior guideline include a consumer added to the update group, evidence from 42 new systematic reviews, enhanced information on patient education and counseling, a new algorithm to clarify action statement relationships, expanded opportunities for watchful waiting (without antibiotic therapy) as initial therapy of acute bacterial rhinosinusitis (ABRS), and 3 new recommendations for managing chronic rhinosinusitis (CRS).

Purpose. The purpose of this multidisciplinary guideline is to identify quality improvement opportunities in managing adult rhinosinusitis and to create explicit and actionable recommendations to implement these opportunities in clinical practice. Specifically, the goals are to improve diagnostic accuracy for adult rhinosinusitis, promote appropriate use of ancillary tests to confirm diagnosis and guide management, and promote judicious use of systemic and topical therapy, which includes radiography, nasal endoscopy, computed tomography, and testing for allergy and immune function. Emphasis was also placed on identifying multiple chronic conditions that would modify management of rhinosinusitis, including asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia.

Action statements. The update group made strong recommendations that clinicians (1) should distinguish presumed ABRS from acute rhinosinusitis (ARS) caused by viral upper respiratory infections and noninfectious conditions and (2) should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for adults with uncomplicated ABRS; (2) should prescribe amoxicillin with or without clavulanate as first-line therapy for 5 to 10 days (if a decision is made to treat ABRS with an antibiotic); (3) should reassess the patient to confirm ABRS, exclude other causes of illness, and detect complications if the patient worsens or fails to improve with the initial management option by 7 days after diagnosis or worsens during the initial management; (4) should distinguish CRS and recurrent ARS from isolated episodes of ABRS and other causes of sinonasal symptoms; (5) should assess the patient with CRS or recurrent ARS for multiple chronic conditions that would modify management, such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia; (6) should confirm the presence or absence of nasal polyps in a patient with CRS; and (7) should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS. The update group stated as options that clinicians may (1) recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of viral rhinosinusitis; (2) recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of ABRS; and (3) obtain testing for allergy and immune function in evaluating a patient with CRS or recurrent ARS. The update group made recommendations that clinicians (1) should not obtain radiographic imaging for patients who meet diagnostic criteria for ARS, unless a complication or alternative diagnosis is suspected, and (2) should not prescribe topical or systemic antifungal therapy for patients with CRS.

Keywords

adult sinusitis, rhinosinusitis

Received November 18, 2014; revised January 6, 2014; accepted January 20, 2015.

Differences from Prior Guideline

This clinical practice guideline is as an update, and replacement, for an earlier guideline published in 2007 by the American Academy of Otolaryngology—Head and Neck Surgery Foundation (AAO-HNS).1 An update was planned...
for 5 years after the initial publication date and was further necessitated by new primary studies and systematic reviews that might suggest a need for modifying clinically important recommendations. Changes in content and methodology from the prior guideline include the following:

- Addition of a consumer advocate to the guideline development group
- New evidence from 5 clinical practice guidelines, 42 systematic reviews, and 70 randomized controlled trials
- Emphasis on patient education and counseling with new explanatory tables
- Expanded action statement profiles to explicitly state quality improvement opportunities, confidence in the evidence, intentional vagueness, and differences of opinion
- Enhanced external review process to include public comment and journal peer review
- New algorithm to clarify decision-making and action statement relationships
- Extension of watchful waiting (without antibiotic therapy) as an initial management strategy to all patients with uncomplicated acute bacterial rhinosinusitis (ABRS) regardless of severity, not just patients with “mild” illness (prior guideline)
- Change in recommendation from first-line antibiotic therapy for acute bacterial rhinosinusitis amoxicillin, with or without clavulanate, from amoxicillin alone (prior guideline)
- Addition of asthma as a chronic condition that modifies management of chronic rhinosinusitis (CRS)
- Three new key action statements on managing CRS that focus on polyps as a modifying factor, a recommendation in favor of topical intranasal therapy (saline irrigations, corticosteroids), and a recommendation against using topical or systemic antifungal agents

Introduction

Sinusitis affects about 1 in 8 adults in the United States, resulting in over 30 million annual diagnoses. The direct cost of managing acute and chronic sinusitis exceeds $11 billion per year, with additional expense from lost productivity, reduced job effectiveness, and impaired quality of life. More than 1 in 5 antibiotics prescribed in adults are for sinusitis, making it the fifth most common diagnosis responsible for antibiotic therapy. Despite the high prevalence and economic impact of sinusitis, considerable practice variations exist across and within the multiple disciplines involved in managing the condition.

The target patient for this guideline is age 18 years or older with a clinical diagnosis of uncomplicated rhinosinusitis:

- **Rhinosinusitis** is defined as symptomatic inflammation of the paranasal sinuses and nasal cavity. The term *rhinosinusitis* is preferred because sinusitis is almost always accompanied by inflammation of the contiguous nasal mucosa. Therefore, *rhinosinusitis* is used in the remainder of the guideline.
- **Uncomplicated rhinosinusitis** is defined as rhinosinusitis without clinically evident extension of inflammation outside the paranasal sinuses and nasal cavity at the time of diagnosis (eg, no neurologic, ophthalmologic, or soft tissue involvement).

Rhinosinusitis may be classified by duration as **acute rhinosinusitis** (ARS) if less than 4 weeks’ duration or as **chronic rhinosinusitis** (CRS) if lasting more than 12 weeks, with or without acute exacerbations. ARS may be classified further by presumed etiology, based on symptoms and time course (Key Action Statement 1), into acute *bacterial* rhinosinusitis (ABRS) or *viral* rhinosinusitis (VRS). Distinguishing presumed bacterial vs viral infection is important because antibiotic therapy is inappropriate for the latter. When patients have 4 or more annual episodes of rhinosinusitis, without persistent symptoms in between, the condition is termed **recurrent ARS**.

Nearly all authorities agree that CRS begins after 12 weeks’ duration, but opinions about the duration of ARS vary, with some defining illness up to 12 weeks as ARS. We agree with other guideline groups that define ARS as up to 4 weeks’ duration but recognize that this boundary is based more on consensus than research evidence. Moreover, very limited data are available on rhinosinusitis lasting 4 to 12 weeks, sometimes called **subacute** rhinosinusitis. We do not distinguish rhinosinusitis in this time frame as an explicit entity in the guideline, and decisions about whether such patients are more like ARS or CRS must therefore be individualized.
Guideline Purpose

The purpose of this multidisciplinary guideline is to identify quality improvement opportunities in managing adult rhinosinusitis and to create explicit and actionable recommendations to implement these opportunities in clinical practice. Specifically, the goals are to improve diagnostic accuracy for adult rhinosinusitis, promote judicious use of systemic and topical therapy, and promote appropriate use of ancillary tests to confirm diagnosis and guide management, which include radiography, nasal endoscopy, computed tomography, and testing for allergy and immune function. Emphasis was also placed on identifying multiple chronic conditions that would modify management of rhinosinusitis, including asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia.

The guideline is intended for all clinicians who are likely to diagnose and manage adults with rhinosinusitis and applies to any setting in which an adult with rhinosinusitis would be identified, monitored, or managed. This guideline, however, does not apply to patients younger than 18 years or to patients of any age with complicated rhinosinusitis.

The guideline will not consider management of the following clinical presentations, although differential diagnosis for these conditions and bacterial rhinosinusitis will be discussed: allergic rhinitis, eosinophilic nonallergic rhinitis, vasomotor rhinitis, invasive fungal rhinosinusitis, allergic fungal rhinosinusitis, vascular headaches, and migraines. Similarly, the guideline will not consider management of rhinosinusitis in patients with the following modifying factors but will discuss the importance of assessing patients with recurrent ARS or CRS for their presence: cystic fibrosis, immotile cilia disorders, ciliary dyskinesia, immune deficiency, prior history of sinus surgery, and anatomic abnormalities (eg, deviated nasal septum).

Surgical management of CRS is not discussed in this guideline because of insufficient evidence (eg, randomized controlled trials) for evidence-based recommendations.

Burden of Rhinosinusitis

Twelve percent of the US population (nearly 1 in 8 adults) reported being diagnosed with rhinosinusitis in the prior 12 months in a 2012 national health survey. Rhinosinusitis was diagnosed more frequently than hay fever (7%), bronchitis (4%), or chronic obstructive pulmonary disease (4%), and the individuals surveyed were almost as likely to receive a diagnosis of rhinosinusitis as they were of asthma (13%).

The broad category of rhinosinusitis in the preceding paragraph includes ARS and CRS. Most ARS begins when a viral upper respiratory infection (URI) extends into the paranasal sinuses, which may be followed by bacterial infection. About 20 million cases of presumed bacterial ARS (ABRS) occur annually in the United States, rendering it one of the most common conditions encountered by clinicians. The importance of ABRS relates not only to prevalence but also to the potential for uncommon, but serious, complications that include meningitis, brain abscess, orbital cellulitis, and orbital abscesses.

National ambulatory care data from 2006 to 2010 revealed that rhinosinusitis accounted for more outpatient antibiotic prescriptions than any other diagnosis. Despite guidelines that encourage judicious antibiotic use for ARS, they are prescribed in about 82% of visits. From 2006 to 2010, rhinosinusitis accounted for 11% of all primary care antibiotic-related visits, with ARS accounting for 3.9% and CRS accounting for 7.1%. ARS and CRS combined accounted for more primary ambulatory care visits with antibiotic prescriptions than any other diagnosis or commonly grouped diagnoses.

ARS has significant economic implications. The cost of antibiotic treatment failure, including additional prescriptions, outpatient visits, tests, and procedures, contributes to a substantial total ARS-related health care expenditure of more than $3 billion per year in the United States. The average patient with recurrent ARS incurs about $1100 per year in total direct health costs. Aside from the direct treatment costs, decreased productivity and lost work days contribute to an even greater indirect health care cost associated with ABRS and recurrent ARS.

CRS also has significant socioeconomic implications. In 2001, there were 18.3 million office visits for CRS, most of which resulted in prescription medications. Patients with CRS visit primary care clinicians twice as often as those without the disorder and have 5 times as many prescriptions filled. A survey in 2007 found that approximately $8.3 billion is spent annually on CRS, primarily on prescription drugs and office-based care. Surgery for CRS, which is performed nearly 250,000 times annually in the United States, averages a cost of $7700 per patient. Average annual per-patient spending is $770, which increases to $2450 in the year prior to surgery.

The indirect cost of CRS is substantial, making it potentially more important than the direct cost. CRS accounts for, on average, 1 to 2 lost workdays per patient per year and 73 million days of restricted activity. In contrast, those with medically refractory CRS miss 18 annual workdays. Patients with CRS are absent from work because of sinusitis 6.5% of the time, have a 36% reduction in on-the-job effectiveness, and suffer a 38% loss of productivity. Compared with patients without CRS, patients with CRS have greater activity limitations, work limitations, and social limitations. The overall annual productivity cost for refractory CRS is estimated at $10,077 per patient.

CRS can also have a substantial impact on health-related quality of life. Patients with CRS referred to otolaryngologists score significantly lower on measures of bodily pain and social functioning than do those with angina, back pain, congestive heart failure, and chronic obstructive pulmonary disease. Similarly, patients with CRS have health utility scores that are worse than many chronic diseases, including congestive heart failure, coronary artery disease, and chronic obstructive pulmonary disease. Moreover, treatment of CRS can improve health state utility values and substantially reduce fatigue and bodily pain.

Methods

General Methods and Literature Search

In developing this update of the evidence-based clinical practice guideline, the methods outlined in the AAO-HNSF
Guideline Development Manual, third edition, were followed explicitly.32

An executive summary of the original adult sinusitis guideline1 was first sent to a panel of expert reviewers who were asked to assess the key action statements and decide if they should be revised, be kept as stands, or removed based on relevancy, omissions, or controversies that the guideline spurred and to identify any new literature or treatments that might affect the guideline recommendations. The reviewers concluded that the original guideline action statements remained valid but should be updated with minor modifications. Suggestions were also made for new key action statements.

A systematic literature search was performed by an information specialist to identify systematic reviews, clinical practice guidelines, and randomized controlled trials published since the prior guideline (2007). The original MEDLINE search was updated from December 2006 to March 2014 to include Medline, National Guidelines Clearinghouse, Cochrane Database of Systematic Reviews, Excerpta Medica database (EMBASE), Cumulative Index to Nursing and Allied Health (CINAHL), and Web of Science using the search string “(sinusit* OR rhinosinusit*).” The initial English-language search identified 54 potential clinical practice guidelines, 166 systematic reviews, and 352 randomized controlled trials (RCTs). Systematic reviews were emphasized and included if they met quality criteria of (a) clear objective and methods, (b) an explicit search strategy, and (c) valid data extraction. Additional evidence was identified, as needed, with targeted searches to support needs of the guideline development group in updating sections of the guideline text. After assessing quality and relevance of the initial search results, we retained 5 guidelines, 42 systematic reviews, and 70 RCTs.

The AAO-HNSF assembled a guideline update group (GUG) representing the disciplines of otolaryngology–head and neck surgery, infectious disease, family medicine, allergy and immunology, advanced practice nursing, and a consumer advocate. The GUG also included a staff liaison from AAO-HNSF, but this individual was not a voting member of the GUG and served only in an editorial capacity in writing the guideline. Although radiology was represented on the original guideline development group, they were excluded from the update since the AAO-HNSF had recently published a clinical consensus statement on imaging for sinusitis.33 We did, however, solicit radiology feedback about pertinent statements to ensure they remained valid and current.

The GUG had several conference calls and one in-person meeting, during which comments from the expert panel review and the literature search were reviewed for each key action statement. The GUG then decided to leave the statement unaltered, change slightly, or rewrite the statement based on the impact of the literature search and the reviewer comments. The supporting text was then edited to explain any changes from the original key action statement, and the recommendation level was modified accordingly.

The evidence profile for each statement was then converted into an action statement profile, which was moved up in the text to immediately follow the action statement. Statements about the quality improvement opportunity, level of confidence in the evidence, differences of opinion, intentional vagueness, and any exclusion to which the action statement does not apply were added to the action statement profiles. These additions reflect the current methodology for guideline development by the AAO-HNSF and conform to the Institute of Medicine’s standards for developing trustworthy guidelines.32 The updated guideline then underwent Guideline Implementability Appraisal (GLIA) to appraise adherence to methodologic standards, to improve clarity of recommendations, and to predict potential obstacles to implementation.34 The GUG received summary appraisals in June and modified an advanced draft of the guideline based on the appraisal.

The final draft of the updated clinical practice guideline was revised based on comments received during multidisciplinary peer review, open public comment, and journal editorial peer review. The recommendations contained in the guideline are based on the best available published data through March 2014. Where data were lacking, a combination of clinical experience and expert consensus was used. A scheduled review process will occur at 5 years from publication or sooner if new, compelling evidence warrants earlier consideration.

Classification of Evidence-Based Statements
Guidelines are intended to reduce inappropriate variations in clinical care, to produce optimal health outcomes for patients, and to minimize harm. The evidence-based approach to guideline development requires that the evidence supporting a policy be identified, appraised, and summarized and that an explicit link between evidence and statements be defined. Evidence-based statements reflect both the quality of evidence and the balance of benefit and harm that are anticipated when the statement is followed. The definitions for evidence-based statements33 are listed in Tables 1 and 2.

Guidelines are never intended to supersede professional judgment; rather, they may be viewed as a relative constraint on individual clinician discretion in a particular clinical circumstance. Less frequent variation in practice is expected for a strong recommendation than might be expected with a recommendation. Options offer the most opportunity for practice variability.36 Clinicians should always act and decide in a way that they believe will best serve their individual patients’ interests and needs, regardless of guideline recommendations. Guidelines represent the best judgment of a team of experienced clinicians and methodologists addressing the scientific evidence for a particular topic.35

Making recommendations about health practices involves value judgments on the desirability of various outcomes associated with management options. Values applied by the GUG sought to minimize harm, diminish unnecessary and inappropriate therapy, and reduce the unnecessary use of systemic antibiotics. A major goal of the panel was to be transparent and explicit about how values were applied and to document the process.
Recommendation

A recommendation means the benefits exceed the established “stake” in an issue.\(^3\) In some clearly identified circumstances, strong recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms.

Option

An option means that either the quality of evidence is suspect (Grade D)\(^4\) or that well-done studies (Grade A, B, or C)\(^3\) show little clear advantage to one approach vs another.

Financial Disclosure and Conflicts of Interest

The cost of developing this guideline, including travel expenses of all panel members, was covered in full by the AAO-HNSF. Potential conflicts of interest for all panel members in the past 5 years were compiled and distributed before the first conference call. After review and discussion of these disclosures,\(^3\) the panel concluded that individuals with potential conflicts could remain on the panel if they (1) reminded the panel of potential conflicts before any related discussion, (2) recused themselves from a related discussion if asked by the panel, and (3) agreed not to discuss any aspect of the guideline with industry before publication. Last, panelists were reminded that conflicts of interest extend beyond financial relationships and may include personal experiences, how a participant earns a living, and the participant’s previously established “stake” in an issue.\(^3\)

Rhinosinusitis Guideline Evidence-Based Statements

Each evidence-based statement is organized in a similar fashion: an evidence-based key action statement in bold, followed by the strength of the recommendation in italics. Each key action statement is followed by an “action statement profile,” which explicitly states the quality improvement opportunity, aggregate evidence quality, level of confidence in evidence (high, medium, low), benefit, harms, risks, costs, and a benefits-harm assessment. In addition, there are statements of any value judgments, the role of patient (caregiver) preferences, clarification of any intentional vagueness by the panel, exceptions to the statement, any differences of opinion, and a repeat statement of the strength of the recommendation. Several paragraphs subsequently discuss the evidence base supporting the statement. An overview of each evidence-based statement in this guideline can be found in Table 3, and the relationship between statements is illustrated in Figure 1.

The role of patient preference in decision making deserves further clarification. For some statements, where the evidence base demonstrates clear benefit, although the role of patient preference for a range of treatments may not be relevant, clinicians should provide patients with clear and comprehensible information on the benefits to facilitate patient understanding and shared decision making, which leads to better patient adherence and outcomes. In cases where evidence is weak or benefits are unclear, the practice of shared decision making, again where the management decision is made by a collaborative effort between the clinician and an informed patient, is extremely useful. Factors related to patient preference include (but are not limited to) absolute benefits (numbers needed to treat), adverse effects (number needed to harm), cost of drugs or procedures, and frequency and duration of treatment.

STATEMENT 1A. DIFFERENTIAL DIAGNOSIS OF ACUTE RHINOSINUSITIS: Clinicians should distinguish presumed acute bacterial rhinosinusitis (ABRS) from acute rhinosinusitis caused by viral upper respiratory infections and noninfectious conditions. A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis (purulent nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without

---

Table 1. Strength of Action Terms in Guideline Statements and Implied Levels of Obligation.

<table>
<thead>
<tr>
<th>Strength</th>
<th>Definition</th>
<th>Implied Obligation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong Recommendation</td>
<td>A strong recommendation means the benefits of the recommended approach clearly exceed the harms (or, in the case of a negative recommendation, the harms clearly exceed the benefits) and that the quality of the supporting evidence is high (Grade A or B).(^4) In some clearly identified circumstances, strong recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms.</td>
<td>Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present.</td>
</tr>
<tr>
<td>Recommendation</td>
<td>A recommendation means the benefits exceed the harms (or, in the case of a negative recommendation, that the harms exceed the benefits), but the quality of evidence is not as high (Grade B or C).(^4) In some clearly identified circumstances, recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits outweigh the harms.</td>
<td>Clinicians should also generally follow a recommendation but should remain alert to new information and sensitive to patient preferences.</td>
</tr>
<tr>
<td>Option</td>
<td>An option means that either the quality of evidence is suspect (Grade D)(^4) or that well-done studies (Grade A, B, or C)(^3) show little clear advantage to one approach vs another.</td>
<td>Clinicians should be flexible in their decision making regarding appropriate practice, although they may set bounds on alternatives; patient preference should have a substantial influencing role.</td>
</tr>
</tbody>
</table>

\(^{3}\)See Table 2 for definitions of evidence grades.
evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms, or (b) symptoms or signs of acute rhinosinusitis worsen within 10 days after an initial improvement (double worsening). Strong recommendation based on diagnostic studies with minor limitations and a preponderance of benefit over harm.

**Action Statement Profile**

- **Quality improvement opportunity**: Avoid inappropriate use of antibiotics for presumed viral infections
- **Aggregate evidence quality**: Grade B, systematic reviews, diagnostic studies with minor limitations regarding signs and symptoms associated with acute bacterial rhinosinusitis (ABRS)
- **Level of confidence in evidence**: Medium
- **Benefit**: Decrease inappropriate use of antibiotics for nonbacterial illness; distinguish noninfectious conditions from rhinosinusitis
- **Harms, risks, costs**: Risk of misclassifying acute bacterial rhinosinusitis as viral or vice versa
- **Benefits-harm assessment**: Preponderance of benefit over harm
- **Value judgments**: Importance of avoiding inappropriate antibiotic treatment of viral or nonbacterial illness; emphasis on clinical signs and symptoms for initial diagnosis; importance of avoiding unnecessary diagnostic tests
- **Intentional vagueness**: None
- **Role of patient preferences**: None
- **Exceptions**: None
- **Policy level**: Strong recommendation
- **Differences of opinion**: None regarding the persistent and double-worsening presentations of ABRS; minor regarding whether to include a severe pattern of ABRS presentation (1 group member was in favor; 9 against)

**Supporting Text**

The purpose of this statement is to emphasize the importance of differentiating acute bacterial rhinosinusitis (ABRS) from acute rhinosinusitis (ARS) caused by viral upper respiratory infections to prevent unnecessary treatment with antibiotics. This also helps the clinician avoid ordering unnecessary diagnostic tests, thus controlling costs and improving quality of care. In contrast to the version of this statement in the original sinusitis guideline, we changed the diagnostic criteria to include not just the persistence of signs and symptoms beyond 10 days but failure to improve in 10 days, for greater specificity in distinguishing presumed bacterial infection for persistent, but resolving, viral illness.

This key action statement is also in line with the Choosing Wisely initiative of the American Board of Internal Medicine Foundation. This initiative was launched to help physicians and patients engage in conversations about the overuse of tests and procedures and support physician efforts to help patients make smart and effective care choices. Having clear, actionable criteria for distinguishing presumed bacterial ARS from viral infection is a prerequisite for judicious antibiotic therapy. Without such criteria, antibiotics are more likely to be inappropriately prescribed for viral illness, adding to the global problem of rising bacterial resistance that is directly correlated with community antibiotic use.

**Cardinal Symptoms of Acute Rhinosinusitis**

Acute rhinosinusitis is diagnosed when a patient presents with up to 4 weeks of purulent (not clear) nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both (Table 4). Nasal obstruction without purulent nasal drainage is not consistent with ARS and is beyond the scope of this guideline. Similarly, facial pain without purulent nasal drainage is not consistent with ARS, even though many patients present with a history of self-reported or physician-diagnosed “sinus”
headache, which is often related to migraines and is responsive to migraine therapy.45,46 When a patient meets the criteria for ARS in Table 4, the clinician should distinguish between viral and bacterial infection.49 Although there is no high-level evidence showing that symptom duration and purulent discharge can reliably distinguish presumed bacterial vs viral ARS,50 the GUG considered the criteria in Table 4 to be best for this purpose based on first principles, subsidiary evidence, and expert consensus, as explained in the remainder of this section.

Table 3. Summary of Evidence-Based Statements.

<table>
<thead>
<tr>
<th>Statement</th>
<th>Action</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A. Differential diagnosis</td>
<td>Clinicians should distinguish presumed ABRS from ARS caused by viral upper respiratory infections and noninfectious conditions. A clinician should diagnose ARS when (a) symptoms or signs of ARS (purulent nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms, or (b) symptoms or signs of ARS worsen within 10 days after an initial improvement (double worsening).</td>
<td>Strong recommendation</td>
</tr>
<tr>
<td>1B. Radiographic imaging and ARS</td>
<td>Clinicians should not obtain radiographic imaging for patients who meet diagnostic criteria for ARS, unless a complication or alternative diagnosis is suspected.</td>
<td>Recommendation (against imaging)</td>
</tr>
<tr>
<td>2. Symptomatic relief of VRS</td>
<td>Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS.</td>
<td>Option</td>
</tr>
<tr>
<td>3. Symptomatic relief of ABRS</td>
<td>Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of ABRS.</td>
<td>Option</td>
</tr>
<tr>
<td>4. Initial management of ABRS</td>
<td>Clinicians should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for adults with uncomplicated ABRS. Watchful waiting should be offered only when there is assurance of follow-up, such that antibiotic therapy is started if the patient’s condition fails to improve by 7 days after ABRS diagnosis or if it worsens at any time.</td>
<td>Recommendation</td>
</tr>
<tr>
<td>5. Choice of antibiotic for ABRS</td>
<td>If a decision is made to treat ABRS with an antibiotic agent, the clinician should prescribe amoxicillin with or without clavulanate as first-line therapy for 5 to 10 days for most adults.</td>
<td>Recommendation</td>
</tr>
<tr>
<td>6. Treatment failure for ABRS</td>
<td>If the patient worsens or fails to improve with the initial management option by 7 days after diagnosis or worsens during the initial management, the clinician should reassess the patient to confirm ARS, exclude other causes of illness, and detect complications. If ARS is confirmed in the patient initially managed with observation, the clinician should begin antibiotic therapy. If the patient was initially managed with an antibiotic, the clinician should change the antibiotic.</td>
<td>Recommendation</td>
</tr>
<tr>
<td>7A. Diagnosis of CRS or recurrent ARS</td>
<td>Clinicians should distinguish CRS and recurrent ARS from isolated episodes of ABRS and other causes of sinonasal symptoms.</td>
<td>Recommendation</td>
</tr>
<tr>
<td>7B. Objective confirmation of a diagnosis of CRS</td>
<td>The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography.</td>
<td>Strong recommendation</td>
</tr>
<tr>
<td>8. Modifying factors</td>
<td>Clinicians should assess the patient with CRS or recurrent ARS for multiple chronic conditions that would modify management, such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia.</td>
<td>Recommendation</td>
</tr>
<tr>
<td>9. Testing for allergy and immune function</td>
<td>The clinician may obtain testing for allergy and immune function in evaluating a patient with CRS or recurrent ARS.</td>
<td>Option</td>
</tr>
<tr>
<td>10. CRS with polyps</td>
<td>The clinician should confirm the presence or absence of nasal polyps in a patient with CRS.</td>
<td>Recommendation</td>
</tr>
<tr>
<td>11. Topical intranasal therapy for CRS</td>
<td>Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.</td>
<td>Recommendation</td>
</tr>
<tr>
<td>12. Antifungal therapy for CRS</td>
<td>Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.</td>
<td>Recommendation (against therapy)</td>
</tr>
</tbody>
</table>

Abbreviations: ABRS, acute bacterial rhinosinusitis; ARS, acute rhinosinusitis; CRS, chronic rhinosinusitis; VRS, viral rhinosinusitis.
The rationale for selecting 3 cardinal symptoms is based on their high sensitivity and their relatively high specificity for ABRS, especially when considering the time interval of persistence for 10 days or longer.\textsuperscript{51-53} Purulent (infected, colored, or oozing) nasal drainage predicts presence of bacteria on antral aspiration when reported as purulent rhinorrhea by the patient, when manifest as postnasal drip or purulent discharge in the posterior pharynx, or when observed in the nasal cavity or near the sinus ostium.\textsuperscript{54,55} Purulent rhinorrhea also predicts radiographic evidence of ABRS.\textsuperscript{56,57} Facial or dental pain also

ARS, acute RS; AB, acute bacterial RS; CRS, chronic RS; KAS, key action statement; RS, rhinosinusitis; URI, upper respiratory infection

Figure 1. Algorithm showing the interrelationship of guideline key action statements. ABRS, acute bacterial rhinosinusitis; ARS, acute rhinosinusitis; CRS, chronic rhinosinusitis; KAS, key action statement; URI, upper respiratory infection.
Specific sinuses involved. Last, patient complaints of nasal volume (edema) localized over the involved cheek bone or gestion of the capillaries (erythema) or abnormally large fluid ing nasal obstruction, swelling, redness of the skin due to con-

absence of the following: altered (hyponasal) speech indicat-

and neck. Particular attention should be paid to the presence or

measurement of vital signs (temperature, pulse, blood pres-

above.

system and instead focus on the 3 cardinal features outlined

consensus reports, more recent reports abandoned this

major and minor symptoms were used to define ARS in early

URI likely contributes to the specificity of these symptoms for

ABRS, but the extent to which this is true has not been quanti-

physician's history of viral URI likely contributes to the specificity of these symptoms for

ABRS, but the extent to which this is true has not been quanti-

ABRS, but the extent to which this is true has not been quanti-

culture of secretions from the nasal cavity or nasopharynx

Table 4. Acute Rhinosinusitis Definitions.

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute rhinosinusitis (ARS)</td>
<td>Up to 4 weeks of purulent nasal drainage (anterior, posterior, or both) accompanied by nasal obstruction, facial pain-pressure-fullness, or both.</td>
</tr>
<tr>
<td>Viral rhinosinusitis (VRS)</td>
<td>Acute rhinosinusitis that is caused by, or is presumed to be caused by, viral infection. A clinician should diagnose VRS when:</td>
</tr>
<tr>
<td>Acute bacterial rhinosinusitis (ABRS)</td>
<td>Acute rhinosinusitis that is caused by, or is presumed to be caused by, bacterial infection. A clinician should diagnose ABRS when:</td>
</tr>
</tbody>
</table>

*Facial pain-pressure-fullness in the absence of purulent nasal discharge is insufficient to establish a diagnosis of ARS.

predicts ABRS, but the location correlates poorly with the specific sinuses involved. Last, patient complaints of nasal obstruction correlate with objective measures, such as rhino-

manometry or nasal peak flow rate. Since the usual clinical dilemma is to differentiate ABRS from VRS, the specificity of ABRS symptoms has typically been studied in this context. The antecedent history of viral URI likely contributes to the specificity of these symptoms for ABRS, but the extent to which this is true has not been quanti-

Additional signs and symptoms of ABRS include fever, cough, fatigue (malaise), reduced sense of smell (hyposmia), lack of the sense of smell (anosmia), maxillary dental pain, and ear fullness or pressure. Although combinations of major and minor symptoms were used to define ARS in early consensus reports, more recent reports abandoned this system and instead focus on the 3 cardinal features outlined above.

The initial diagnostic evaluation for ARS should include measurement of vital signs (temperature, pulse, blood pressure, respiratory rate) and a physical examination of the head and neck. Particular attention should be paid to the presence or absence of the following: altered (hyponasal) speech indicating nasal obstruction, swelling, redness of the skin due to congestion of the capillaries (erythema) or abnormally large fluid volume (edema) localized over the involved cheek bone or periorbital area; palpable cheek tenderness or percussion tenderness of the upper teeth; purulent drainage in the nose or posterior pharynx; and signs of extra-sinus involvement (orbital or facial cellulitis, orbital protrusion, abnormalities of eye movement, neck stiffness). However, of these physical findings, the only finding shown to have diagnostic value is that of purulence in the nasal cavity or posterior pharynx as discussed above.

Culture of secretions from the nasal cavity or nasopharynx does not differentiate ABRS from VRS, because nasal cultures correlate poorly with maxillary sinus cultures obtained by direct aspiration. A culture of secretions from the middle meatus guided by endoscopy has better correlation, but its role in routine management of uncomplicated ABRS has not been established.

**Transition from Viral to Bacterial Infection**

Only about 0.5 to 2.0% of VRS episodes are complicated by bacterial infection. Antecedent viral infection can promote ABRS by obstructing sinus drainage during the nasal cycle, promoting growth of bacterial pathogens that colonize the nose and nasopharynx, and depositing nasal bacteria into the sinuses during nose-blowing. Although ABRS is often considered a transition from a preceding viral URI, bacterial infection can develop at any time during the course of the illness. The concept of a transition, however, is useful for management decisions, especially when considering the time course of VRS and which disease patterns are most likely to be associated with bacterial infection.

In the first 3 to 4 days of illness VRS cannot be differentiated from an early-onset ABRS; therefore, only patients with unusually severe presentations or extra-sinus manifestations of infection are presumed to have a bacterial illness. Similarly,
Meltzer and coworkers\textsuperscript{13} defined a special circumstance of explicitly highlighting this subgroup of patients with ABRS. Others have supported a “severe” presentation of ABRS if the patient presented with severe symptoms at the onset or has high fever (>39°C or 102°F) and purulent discharge or facial pain lasting at least 3 to 4 consecutive days at the beginning of illness.

We recommend that patients be engaged in understanding what causes ARS and why it is important to distinguish presumed viral ARS from ABRS. The patient information sheet in Table 5 could be used as a teaching aid to conveniently communicate this information.

\begin{figure}[h]
\centering
\includegraphics[width=0.5\textwidth]{symptom_prevalence.png}
\caption{Symptom prevalence by day for rhinovirus illness (data from Gwaltney 1967).\textsuperscript{67}}
\end{figure}

between 5 and 10 days of persistent symptoms are consistent with VRS or may represent the beginning stages of ABRS. In this time period, however, a pattern of initial improvement followed by worsening (“double worsening”) is consistent with ABRS.\textsuperscript{13,56,57} Beyond 10 days, residual sinus mucosal thickness induced by the virus may persist, usually in the absence of active viral infection, but the probability of confirming a bacterial infection by sinus aspiration is about 60\%.\textsuperscript{66}

Gwaltney and colleagues\textsuperscript{67} studied the time course of signs and symptoms of spontaneous rhinovirus infections (Figure 2). Typical symptoms peak at days 2 to 3 and wane thereafter but may persist 14 days or longer. Symptoms of VRS may persist for longer than 10 days, but they gradually decrease in severity. Therefore, the GUG decided to change the statement from “A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis are present 10 days or more beyond the onset of upper respiratory symptoms” to “A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms.”

Fever is present in some patients with VRS in the first few days of illness (Figure 2) but does not predict bacterial infection as an isolated diagnostic criterion. Fever has a sensitivity and specificity of only about 50\% for ABRS.\textsuperscript{52,53} A systematic review concluded that evidence was lacking regarding the ability of fever and facial/dental pain to distinguish ABRS from VRS.\textsuperscript{66} For this reason, we did not include fever as a cardinal sign/symptom in diagnosing ABRS.

Although our GUG concluded that evidence was insufficient to support a “severe” presentation of ABRS, others have explicitly highlighted this subgroup of patients with ABRS. Meltzer and coworkers\textsuperscript{13} defined a special circumstance of ABRS when purulent nasal discharge for 3 to 4 days was accompanied by high fever. “High fever” was not defined, but the criterion only applied to severe disease with a shorter duration of illness. A guideline on sinusitis in children from the American Academy of Pediatrics\textsuperscript{69} considered 3 or more days of concurrent high fever and purulent nasal discharge as a “severe” presentation of ABRS that warrants antibiotic therapy. Similarly, the Infectious Disease Society of America guideline on ABRS\textsuperscript{15} recommended that the clinician consider a diagnosis of ABRS if the patient presented with severe symptoms at the onset or has high fever (>39°C or 102°F) and purulent discharge or facial pain lasting at least 3 to 4 consecutive days at the beginning of illness.

The purpose of this statement is to emphasize that clinicians should not obtain radiographic imaging for patients presenting with uncomplicated acute rhinosinusitis (ARS) to distinguish ABRS from VRS, unless a complication or alternative diagnosis is suspected.
Radiographic imaging of the paranasal sinuses is unnecessary for diagnosis in patients who already meet clinical diagnostic criteria (Table 4) for ABRS. Imaging modalities for the paranasal sinuses include computed tomography (CT) and magnetic resonance (MR) imaging. The American College of Radiology (ACR) has stated that plain films of the sinuses are inaccurate in a high percentage of patients and should be supplanted by CT imaging. A meta-analysis of 6 studies showed that sinus radiography has moderate sensitivity (76%) and specificity (79%) compared with sinus puncture in diagnosing ABRS. Sinus involvement is common in documented viral URIs, making it impossible to distinguish ABRS from VRS based solely on imaging studies. Moreover, clinical criteria may have a comparable diagnostic accuracy to sinus radiography, and radiography is not cost-effective regardless of baseline sinusitis prevalence.

When a complication of ABRS or an alternative diagnosis is suspected, imaging studies may be obtained. Complications of ABRS include orbital, intracranial, or soft tissue involvement. Alternative diagnoses include malignancy and other noninfectious causes of facial pain. Radiographic imaging may also be obtained when the patient has modifying factors or comorbidities that predispose to complications, including diabetes, immune-compromised state, or a history of facial trauma or surgery. CT imaging of the sinuses is appropriate when a complication of ABRS is suspected based on severe headache, facial swelling, cranial nerve palsies, or forward displacement or bulging of the eye (proptosis); CT findings that correlate with ABRS include opacification, air-fluid level, and moderate to severe mucosal thickening. Complications of ABRS are best assessed using iodine contrast-enhanced CT or gadolinium-based MR imaging to identify extra-sinus extension or involvement. Suspected complications are the only indication for MR imaging of the paranasal sinuses in the setting of ABRS.

Limitations of CT imaging include increased cost and radiation dosage. Radiation dose is related to technique and, if appropriate technique is not used, may deliver over 10 times the dosage compared with plain film radiography. With careful choice of technical factors, however, CT dosage can be lowered to 2 times the dose of plain film radiography. Other limitations of CT include lack of specificity for bacterial infection, a relative lack of correlation between localizing symptoms and sinus disease on CT, and the high frequency of incidental abnormal findings in asymptomatic persons.

An alternative to traditional CT imaging is in-office cone-beam CT scanning, which offers advantages of point-of-care testing and possible decreased radiation dosage. The indications for office-based CT imaging are the same as for traditional scanners, and they should not be used for diagnosing or managing uncomplicated ABRS.

**STATEMENT 2. SYMPTOMATIC RELIEF OF VIRAL RHINOSINUSITIS (VRS): Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS.** Option based on randomized controlled trials with limitations and cohort studies with an unclear balance of benefit and harm that varies by patient.

**Action Statement Profile**

- **Quality improvement opportunity:** To encourage consideration of supportive therapies that may improve quality of life for individuals with VRS and furthermore support the avoidance of unnecessary antibiotics in viral disease
- **Aggregate evidence quality:** Grade B and C, randomized controlled trials with limitations and cohort studies
- **Level of confidence in evidence:** Medium
- **Benefit:** Reduction of symptoms; avoidance of unnecessary antibiotics
is not specific for infection. Coloration of nasal discharge is
tion; discolored nasal discharge is a sign of inflammation and
in acute VRS typically peak within 3 days then gradually
T able 4). Symptoms
sary prescribing of antibiotics for viral disease.
VRS is a self-limited disease characterized by cough,
sneezing, rhinorrhea, sore throat, and nasal congestion.67 The
incidence of acute VRS is high, estimated to occur from 2 to 5
times per year in the average adult. In contrast, secondary bac-
terial infection is believed to complicate only 0.5% to 2.0% of
these events.19 While the presentation of viral vs bacterial
infection can be very similar, clinical emphasis on duration,
ilness pattern, and severity of symptoms can help to differen-
tiate between viral vs bacterial infection (Table 4). Symptoms
in acute VRS typically peak within 3 days then gradually
decline and resolve within 10 to 14 days.
Nasal purulence alone does not indicate a bacterial infec-
tion; discolored nasal discharge is a sign of inflammation and
is not specific for infection. Coloration of nasal discharge is
related to the presence of neutrophils not bacteria.49,81-83
Normal transport of mucus requires robust ciliary action. VRS
promotes a vigorous inflammatory response, causing epithe-
elial disruption, edema, and excessive mucus production,
which further impairs normal ciliary function.84
Management of VRS is primarily directed toward relief of
symptoms. Antibiotics are not recommended for treating VRS
since antibiotics are ineffective for viral illness and do not
provide direct symptom relief.85 Therefore, palliative medica-
tions—such as analgesics, anti-inflammatory agents, nasal
saline, decongestants, antihistamines, mucolytics, cough sup-
pressants, and topical or oral corticosteroids—may be used
alone or in varying combinations for symptom relief.16
Analgesics or antipyretic drugs (acetaminophen, ibupro-
fen, or other nonsteroidal anti-inflammatory agents) may be
given for pain or fever. Nasal saline may be palliative and
cleansing with low risk of adverse reactions.13 A Cochrane
review86 reported minor improvements in nasal symptom
scores with the use of nasal saline in both physiologic and
hypertonic concentrations.
Oral decongestants may provide symptomatic relief and
should be considered barring any medical contraindications,
such as hypertension or anxiety. The use of topical deconges-
tant is likely to be palliative, but continuous duration of use
should not exceed 3 to 5 days, as recommended by the manu-
facturers, to avoid rebound congestion and rhinitis medica-
mentosa.87 Clinical experience suggests oral antihistamines
may provide symptomatic relief of excessive secretions and
sneezing, although there are no clinical studies supporting the
use of antihistamines in acute VRS. Guaifenesin (an expecto-
rant) and dextromethorphan (a cough suppressant) are often
used for symptomatic relief of VRS symptoms, but evidence
of clinical efficacy is lacking and decisions regarding their use
are largely related to patient and provider preference.
Topical intranasal steroids may have a role in managing
VRS, even though they do not have a Food and Drug
Administration (FDA) indication for this purpose. A system-
atic review88 found that topical nasal steroids relieved facial
pain and nasal congestion in patients with rhinitis and acute
sinusitis, even though many patients likely had viral illness.
The magnitude of effect, however, was small: 66% of patients
improved with placebo at 14 to 21 days, rising to 73% with
steroid therapy. Adverse events, however, were rare, so the
choice of whether or not the modest clinical benefit of therapy
justifies the cost is a decision that should be based largely on
patient preference.
STATEMENT 3. SYMPTOMATIC RELIEF OF ACUTE
BACTERIAL RHINOSINUSITIS (ABRS): Clinicians
may recommend analgesics, topical intranasal steroids,
and/or nasal saline irrigation for symptomatic relief of
ABRS. Option based on randomized controlled trials with
heterogeneous populations, diagnostic criteria, and outcome
measures with a balance of benefit and harm.
Action Statement Profile
• Quality improvement opportunity: Promote inter-
ventions that may relieve ABRS symptoms (anal-
gesics, saline irrigation, topical intranasal steroids)
and discourage interventions with questionable or
unproven efficacy (antihistamines, systemic steroids,
guaifenesin)
• Aggregate evidence quality: Grade A, systematic
review of RCTs for topical nasal steroids; Grade B,
randomized controlled trials with heterogeneous pop-
ulations, diagnostic criteria, and outcomes measures
for saline irrigation and systemic steroids; grade D,
first principles, for analgesics, decongestants, anti-
histamines (in non-atopic patients) and guaifenesin.
• Level of confidence in evidence: Medium
• Benefit: Relief of facial pain with analgesics, mod-
est increase in symptom relief from topical nasal
steroids (number needed to treat 14), and possible

Supporting Text
The purpose of this statement is to encourage consideration of
supportive therapies that may improve quality of life for indi-
viduals with viral rhinosinusitis (VRS) and to avoid unneces-
sary prescribing of antibiotics for viral disease.

VRS is a self-limited disease characterized by cough,
sneezing, rhinorrhea, sore throat, and nasal congestion.67 The
incidence of acute VRS is high, estimated to occur from 2 to 5
times per year in the average adult. In contrast, secondary bac-
terial infection is believed to complicate only 0.5% to 2.0% of
these events.19 While the presentation of viral vs bacterial
infection can be very similar, clinical emphasis on duration,
ilness pattern, and severity of symptoms can help to differen-
tiate between viral vs bacterial infection (Table 4). Symptoms
in acute VRS typically peak within 3 days then gradually
decline and resolve within 10 to 14 days.

Nasal purulence alone does not indicate a bacterial infec-
tion; discolored nasal discharge is a sign of inflammation and
is not specific for infection. Coloration of nasal discharge is
related to the presence of neutrophils not bacteria.49,81-83
Normal transport of mucus requires robust ciliary action. VRS
promotes a vigorous inflammatory response, causing epithe-
elial disruption, edema, and excessive mucus production,
which further impairs normal ciliary function.84

Management of VRS is primarily directed toward relief of
symptoms. Antibiotics are not recommended for treating VRS
since antibiotics are ineffective for viral illness and do not
provide direct symptom relief.85 Therefore, palliative medica-
tions—such as analgesics, anti-inflammatory agents, nasal
saline, decongestants, antihistamines, mucolytics, cough sup-
pressants, and topical or oral corticosteroids—may be used
alone or in varying combinations for symptom relief.16

Analgesics or antipyretic drugs (acetaminophen, ibupro-
fen, or other nonsteroidal anti-inflammatory agents) may be
given for pain or fever. Nasal saline may be palliative and
cleansing with low risk of adverse reactions.13 A Cochrane
review86 reported minor improvements in nasal symptom
scores with the use of nasal saline in both physiologic and
hypertonic concentrations.

Oral decongestants may provide symptomatic relief and
should be considered barring any medical contraindications,
such as hypertension or anxiety. The use of topical deconges-
tant is likely to be palliative, but continuous duration of use
should not exceed 3 to 5 days, as recommended by the manu-
facturers, to avoid rebound congestion and rhinitis medica-
mentosa.87 Clinical experience suggests oral antihistamines
may provide symptomatic relief of excessive secretions and
sneezing, although there are no clinical studies supporting the
use of antihistamines in acute VRS. Guaifenesin (an expecto-
rant) and dextromethorphan (a cough suppressant) are often
used for symptomatic relief of VRS symptoms, but evidence
of clinical efficacy is lacking and decisions regarding their use
are largely related to patient and provider preference.
Topical intranasal steroids may have a role in managing
VRS, even though they do not have a Food and Drug
Administration (FDA) indication for this purpose. A system-
atic review88 found that topical nasal steroids relieved facial
pain and nasal congestion in patients with rhinitis and acute
sinusitis, even though many patients likely had viral illness.
The magnitude of effect, however, was small: 66% of patients
improved with placebo at 14 to 21 days, rising to 73% with
steroid therapy. Adverse events, however, were rare, so the
choice of whether or not the modest clinical benefit of therapy
justifies the cost is a decision that should be based largely on
patient preference.

STATEMENT 3. SYMPTOMATIC RELIEF OF ACUTE
BACTERIAL RHINOSINUSITIS (ABRS): Clinicians
may recommend analgesics, topical intranasal steroids,
and/or nasal saline irrigation for symptomatic relief of
ABRS. Option based on randomized controlled trials with
heterogeneous populations, diagnostic criteria, and outcome
measures with a balance of benefit and harm.

Action Statement Profile
• Quality improvement opportunity: Promote inter-
ventions that may relieve ABRS symptoms (anal-
gesics, saline irrigation, topical intranasal steroids)
and discourage interventions with questionable or
unproven efficacy (antihistamines, systemic steroids,
guaifenesin)
• Aggregate evidence quality: Grade A, systematic
review of RCTs for topical nasal steroids; Grade B,
randomized controlled trials with heterogeneous pop-
ulations, diagnostic criteria, and outcomes measures
for saline irrigation and systemic steroids; grade D,
first principles, for analgesics, decongestants, anti-
histamines (in non-atopic patients) and guaifenesin.
• Level of confidence in evidence: Medium
• Benefit: Relief of facial pain with analgesics, mod-
est increase in symptom relief from topical nasal
steroids (number needed to treat 14), and possible
symptom relief from saline irrigations; avoidance of adverse events from ineffective therapies

- **Risks, harms, costs:** Side effects of medications, which include local and systemic adverse reactions; cost of medications
- **Benefits-harm assessment:** Balance of benefit and harm
- **Value judgments:** Provide symptomatic relief while minimizing adverse events and costs
- **Intentional vagueness:** We use the broad term symptomatic relief to acknowledge there are several interventions available for this purpose and to encourage a conversation between clinicians and patients about which specific intervention(s) may be best for their specific ABRS symptoms
- **Role of patient preferences:** Large role for shared decision making regarding use of analgesics, topical nasal steroids, and saline irrigation
- **Exceptions:** None
- **Policy level:** Option
- **Differences of opinion:** None

### Supporting Text

The purpose of this statement is to raise awareness of interventions that may be used to provide symptomatic relief of ABRS (analgesics, saline irrigation, topical nasal steroids), to discourage use of interventions with questionable or unproven efficacy (antihistamines, systemic steroids), and to provide information on commonly used interventions (decongestants, guaifenesin) with unknown effects on ABRS symptoms.

Adjuvant treatments for rhinosinusitis that may aid in symptomatic relief include analgesics, decongestants (α-adrenergic), corticosteroids, saline irrigation, and mucolytics. None of these products has been specifically approved by the FDA for use in acute rhinosinusitis (as of March 2014), and only some have data from controlled clinical studies supporting this use. Moreover, existing trials often include cointerventions and a heterogeneous population of patients with viral, recurrent bacterial, chronic, and allergic rhinosinusitis. Nonetheless, clinicians may wish to consider adjuvant therapy for ABRS on an individualized basis, and we therefore provide a brief overview of evidence in the remainder of this section.

### Analgesic Therapy

Pain relief is a major goal in managing ABRS and often a reason that patients with this condition seek health care. Facial pain is a cardinal symptom for diagnosing ABRS (Table 4) and may involve the anterior face, periorbital region, or manifest with diffuse or localized headache. Over-the-counter analgesics, such as nonsteroidal anti-inflammatory drugs or acetaminophen, are usually sufficient to relieve facial pain associated with ABRS. Narcotics are rarely necessary and should be discouraged because of potential adverse events.

### Topical and Oral Steroids

Topical nasal steroids have been used alone or in combination with oral antibiotics for symptomatic relief of ABRS. Prescription drugs studied in these trials include mometasone, fluticasone, flunisolide, and budesonide. An over-the-counter nasal steroid, triamcinolone acetonide, is also available but has not been studied explicitly for ABRS.

A Cochrane review, which included 4 RCTs of topical intranasal steroid vs placebo or no intervention as monotherapy for ABRS, found that steroids increased the rate of symptom improvement from 66% to 73% after 15 to 21 days (risk ratio, 1.10; 95% CI, 1.02-1.18). The studies had low risk of bias, and only minor adverse events were reported, which included epistaxis, headache, and nasal itching. The authors concluded that clinicians should weigh the modest (number needed to treat of 14) but clinically important benefits of intranasal steroid therapy against the associated cost and minor adverse events.

Although intranasal steroid therapy has been used as an adjunct to oral antibiotic therapy for managing ABRS, the results may not apply to patients with sporadic ABRS as defined in this guideline. Dolor and colleagues increased the rate of treatment success for ABRS at 3 weeks from 74% to 93% when adding fluticasone nasal spray to oral cefuroxime, but all the patients studied had a history of CRS or recurrent ARS. Conversely, Williamson and colleagues studied patients with nonrecurrent ARS and found no benefits for amoxicillin alone, or with topical budesonide, over placebo. This study, however, may have included many patients with VRS, because most patients had symptoms for less than 10 days (median of 7 days) and would not meet our diagnostic criteria for ABRS (Table 4).

A Cochrane review of systemic steroids for ABRS found no benefit over placebo when oral steroids were used as monotherapy. Limited data from 5 trials were found to suggest that oral steroids used in combination with antibiotics may have a modest short-term beneficial effect for symptom relief (number needed to treat of 7), but confidence in results was limited by a significant risk of attrition bias caused by missing outcomes. Adverse events were mild (nausea, vomiting, gastric complaints), but the authors conclude that additional research is needed for adequate confidence in the true effect of systemic steroids.

### Saline Irrigation, Decongestants, Antihistamines, and Guaifenesin

Nasal saline irrigation, alone or in conjunction with other adjuvant measures, may improve quality of life, decrease symptoms, and decrease medication use for ABRS, particularly in patients with frequent sinusitis. Buffered hypertonic (3%-5%) saline irrigation showed a modest benefit for ARS in 2 clinical trials. Compared with isotonic saline, hypertonic saline may have a superior anti-inflammatory effect and better ability to thin mucus and transiently improve mucociliary clearance. One randomized controlled trial of patients with the common cold and ARS, however, found no difference in outcomes for hypertonic saline, normal saline, or observation. There are no systematic reviews assessing the use of nasal saline irrigation in ABRS in adults.
Topical and systemic decongestants (sympathomimetics) have been used to treat nasal congestion associated with the common cold for many years. There are no RCTs that specifically study the efficacy of decongestants for ABRS, but 2 small studies have shown that xylometazoline nasal spray reduces congestion of sinus and nasal mucosa on imaging studies and is superior to a single orally administered dose of pseudoephedrine. Another small, nonrandomized study showed improved outcomes when xylometazoline spray was added to antibiotics for ABRS. Topical decongestants should not be used more than 3 to 5 consecutive days without a prolonged intervening drug-free period due to their propensity to cause rebound congestion and rhinitis medicamentosa.

Antihistamines have no role in the symptomatic relief of ABRS in nonatopic patients. No studies support their use in an infectious setting, and antihistamines may worsen congestion by drying the nasal mucosa. Conversely, 1 randomized controlled trial in allergic patients with ABRS showed reduced sneezing and nasal congestion for loratadine vs placebo when used as an adjunct to antibiotics and oral corticosteroids. Antihistamine therapy, therefore, can be considered for patients with ABRS whose symptoms support a significant allergic component. In this regard, second-generation H1-antagonists cause less sedation and anticholinergic side effects than do older first-generation H1-antagonists.

Guaifenesin is a water- and alcohol-soluble agent that is used as an expectorant to loosen phlegm and bronchial secretions. The product is available over the counter and is sometimes recommended to “loosen” nasal discharge, but there is no evidence regarding the effect, if any, on symptomatic relief of ABRS.

STATEMENT 4. INITIAL MANAGEMENT OF ACUTE BACTERIAL RHINOSINUSITIS (ABRS): Clinicians should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for adults with uncomplicated ABRS. Watchful waiting should be offered only when there is assurance of follow-up, such that antibiotic therapy is started if the patient’s condition fails to improve by 7 days after ABRS diagnosis or if it worsens at any time. Recommendation based on systematic reviews of double-blind randomized controlled trials with some heterogeneity in diagnostic criteria and illness severity and a relative balance of benefit and risk.

Action Statement Profile

- Benefit: Promote more informed, shared decision making regarding whether or not to prescribe initial antibiotics for ABRS given the favorable natural history in placebo groups, the small to modest benefits of antibiotic therapy, and the higher rates of adverse events when antibiotics are prescribed; more selective initial use of antibiotics will reduce adverse events and the risk of bacterial resistance
- Risks, harms, costs: Antibiotics could be withheld from patients who would have derived benefit from their use; antibiotics could be prescribed to patients who would have improved equally on their own.
- Benefits-harm assessment: Preponderance of benefit over harm (regarding the decision for initial management)
- Value judgments: Perception by the GUG that watchful waiting, without antibiotics, is an underused strategy for initial management of uncomplicated ABRS, despite existing guidelines and systematic reviews that support this approach.
- Intentional vagueness: No restrictions have been stated for illness severity (eg, mild, moderate, or severe), which was done in the prior guideline, because insufficient evidence to determine that severity would affect outcomes of antibiotic therapy, including the potential for complications.
- Role of patient preferences: Large role for shared decision making
- Exceptions: Complicated sinusitis, immune deficiency, or coexisting bacterial illness; the clinician should also consider the patient’s age, general health, cardiopulmonary status, and comorbid conditions when assessing suitability for watchful waiting.
- Policy level: Recommendation
- Differences of opinion: No difference of opinion regarding the choice to initially observe or prescribe antibiotics (one abstention); minor difference of opinion (1 against, 9 in favor) regarding the decision to remove severity (eg, mild illness) as a criterion for watchful waiting

Supporting Text

The purpose of this statement is to emphasize that both watchful waiting and antibiotic therapy are appropriate, evidence-based strategies for the initial management of uncomplicated ABRS. The precursor to this guideline endorsed watchful waiting without an antibiotic as an option for initial management, even when ABRS signs and symptoms had persisted for 10 days or longer. More recent evidence, however, allows elevating watchful waiting to the status of a recommendation (not just an option). Moreover, whereas the prior guideline restricted watchful waiting to patients with only “mild” ABRS, current evidence supports offering this to patients regardless of illness severity.

Watchful waiting for ABRS refers to deferring antibiotic treatment of selected patients for up to 7 days after diagnosis of ABRS and limiting management to symptomatic relief.
Patients are candidates for watchful waiting when follow-up is ensured and a system is in place that permits reevaluation if the illness persists or worsens. Antibiotics are started if the patient’s condition fails to improve by 7 days following ABRS diagnosis or worsens at any time.

**Outcomes of Placebo vs Antibiotic Therapy**

Four systematic reviews of RCTs, all published since the prior version of this guideline, have addressed the performance of antibiotics compared with placebo for the management of ABRS. All of the analyses included RCTs that diagnosed patients on clinical signs and symptoms only. Some of the included RCTs also used radiology, serology, or microbiology studies to confirm the diagnosis. Collectively, the systematic review findings can be summarized as follows:

- Cure or improvement rates at 7 to 15 days favored antibiotics but the clinical benefit was small: 91% for antibiotic therapy vs 86% for patients who received placebo. The number needed to treat for benefit ranged from 11 to 15 patients and odds ratios for overall treatment effect ranged from 1.25 to 1.87.
- Duration of pain or illness associated with ABRS did not show any consistent relationship to initial management.
- Adverse events were more common in the antibiotic-treated patients (odds ratio, 1.87 to 2.10; number needed to harm, 8.1), but the rate of dropout due to adverse events was small (1%-1.5%) and similar between both groups.
- Complications were similar regardless of initial management.

While the RCTs that comprised these meta-analyses typically excluded from randomization patients with “severe” disease, they did not specifically or consistently define what was meant by this term. As a result, there is no evidence supporting or refuting the stance that patients with more severe ABRS should always be treated with initial antibiotics. One study found ARS patients with pharyngeal purulence to be more likely to benefit from antibiotics. Unfortunately, the literature is otherwise lacking on which patients may benefit more or less from antibiotic therapy. Further, there is no conclusive evidence that increased age or allergic rhinitis predicts a prolonged or chronic course of ABRS or any evidence that older patients benefit more from antibiotic therapy.

This guideline differs from its previous version in no longer restricting watchful waiting to patients with mild to moderate ABRS because evidence is lacking to support additional benefits of antibiotic therapy for more severe presentations. This approach also differs from other guidelines and consensus statements that recommend antibiotics for patients with severe ABRS, manifesting as high fever and severe or worsening facial pain.

**Shared Decision Making with Patients**

Clinicians deciding whether or not to treat ABRS with antibiotics should also solicit and consider patient preference and determine the relevance of existing evidence to their specific practice setting and patient population. Some patients may place great value on avoiding antibiotic therapy, whenever possible, but others may request initial antibiotics because they value the small but significant increase in clinical improvement they provide. Regardless of which initial strategy is used, clinicians should provide patients with clear information on management options, including symptomatic relief (Table 6). Clinicians may also find it helpful to evaluate the patient’s preexisting knowledge and attitudes about antibiotic therapy and ABRS, because they could affect treatment preference.

Some patients will fail a period of watchful waiting and will benefit from antibiotics. To avoid the expense and inconvenience of another office visit in these patients, the clinician may wish to use a WASP (wait-and-see antibiotic prescription) or a SNAP (safety net antibiotic prescription). Such a prescription, with instructions on when to fill, can provide a sense of security for the patient who agrees to initial watchful waiting and is concerned about accessing the clinician to obtain an antibiotic prescription, if necessary. Patients are informed that they should fill the prescription and begin antibiotic therapy if they fail to improve within 7 days or if they worsen at any time. They should also call the physician’s office and let them know they have begun antibiotic therapy.

**STATEMENT 5. CHOICE OF ANTIBIOTIC FOR ACUTE BACTERIAL RHINOSINUSITIS (ABRS): If a decision is made to treat ABRS with an antibiotic agent, the clinician should prescribe amoxicillin with or without clavulanate as first-line therapy for 5 to 10 days for most adults. Recommendations based on randomized controlled trials with heterogeneity and noninferiority design with a preponderance of benefit over harm.**

**Action Statement Profile**

- Quality improvement opportunity: Discourage initial prescribing of antibiotics other than amoxicillin, with or without clavulanate, that may have lower efficacy or have comparable efficacy but more adverse events.
- Aggregate evidence quality: Grade A, systematic reviews of randomized controlled trials with heterogeneity and noninferiority design
- Level of confidence in evidence: Moderate regarding choice of antibiotic but lower regarding the optimal duration of antibiotic therapy because of limited supporting evidence and statistical power
- Benefit: Clinical outcomes that are comparable to broader spectrum antibiotics for initial therapy; potential reduced bacterial resistance by using a narrow-spectrum antibiotic as first-line therapy; cost-effectiveness of amoxicillin vs other antibiotic choices
- Risks, harms, costs: Potential increased gastrointestinal adverse effects with amoxicillin-clavulanate compared with other antibiotics; adverse effects from penicillin allergy.
Table 6. Patient Information Sheet on Treating Acute Bacterial Rhinosinusitis (ABRS).

<table>
<thead>
<tr>
<th>Question</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>How long will it take before I feel better?</td>
<td>Most patients with ABRS feel better within 7 days, and by 15 days, about 90% are cured or improved.</td>
</tr>
<tr>
<td>Is there anything I can do for symptomatic relief?</td>
<td>There are several ways to relieve sinusitis symptoms that should be discussed with your doctor to decide which are best for you: 1. Acetaminophen or ibuprofen can relieve pain and fever. 2. Saline irrigations, or washing out the nose with salt water, can relieve symptoms and remove mucus that is hard to blow out. 3. Nasal steroid sprays can reduce symptoms after 15 days of use, but the benefit is small (about 14 people must use them to get 1 person better), and side effects include headache, nasal itching, and nosebleeds. Decongestants may help you breathe easier and can be taken as a nasal spray (for no more than 3 days in a row to avoid worsening congestion) or by mouth.</td>
</tr>
<tr>
<td>Is there anything I should not do?</td>
<td>Antihistamines and oral steroid medicines should not be used routinely because they have side effects and do not relieve symptoms.</td>
</tr>
<tr>
<td>If I have ABRS, do I have to take an antibiotic?</td>
<td>No, both watchful waiting and antibiotic therapy are proven ways to treat ABRS. Most people get better naturally, and antibiotics only slightly increase symptom relief (about 10 to 15 people must use antibiotics to get 1 more person better after 7-15 days).</td>
</tr>
<tr>
<td>Is there any downside to using antibiotic?</td>
<td>Antibiotics have side effects that include rash, upset stomach, nausea, vomiting, allergic reactions, and causing resistant germs.</td>
</tr>
<tr>
<td>What is “watchful waiting” for ABRS?</td>
<td>Watchful waiting means delaying antibiotic treatment of ABRS for up to 7 days after diagnosis to see if you get better on your own.</td>
</tr>
<tr>
<td>How is watchful waiting done?</td>
<td>Your doctor can give you an antibiotic prescription, but you should only fill the prescription and take the antibiotic if you do not get better after 7 days or if you get worse at any time. If you do use the antibiotic, contact your doctor’s office and let them know.</td>
</tr>
<tr>
<td>If I use an antibiotic, for how many days should I take it?</td>
<td>Antibiotics are usually given for 10 days to treat ABRS, but shorter courses may be equally effective. Ask your doctor about a 5- to 7-day course of antibiotics since side effects are less common.</td>
</tr>
</tbody>
</table>

- Benefits-harm assessment: Preponderance of benefit over harm
- Value judgments: Promote safe and cost-effective initial therapy
- Intentional vagueness: Whether to prescribe amoxicillin or amoxicillin-clavulanate is at the discretion of the clinician, as is the duration of therapy because systematic review has not shown consistent benefits for 10 days of therapy compared with shorter courses. A longer course of therapy may be appropriate for more severe illness or when symptoms persist despite a shorter course.
- Role of patient preferences: Moderate role for shared decision making; large role in determining duration of antibiotic therapy since adverse events are reduced with shorter duration of therapy.
- Exceptions: Patients with penicillin allergy for whom amoxicillin is contraindicated
- Policy level: Recommendation
- Differences of opinion: None

**Supporting Text**

The purpose of this statement is to promote prescribing of antibiotics with known efficacy and safety for ABRS and to reduce prescribing of antibiotics with potentially inferior efficacy because of more limited coverage of the usual pathogens that cause ABRS in adults. A secondary goal is to promote cost-effective antibiotic therapy of ABRS.

The rationale for antibiotic therapy of ABRS is to eradicate bacterial infection from the sinuses, hasten resolution of symptoms, and enhance disease-specific quality of life. Antibiotic therapy should be efficacious, cost-effective, and result in minimal side effects. Dozens of RCTs have assessed the comparative clinical efficacy of antibiotics for ABRS in adults, with many trials either funded by pharmaceutical companies or conducted by authors associated with the pharmaceutical industry.

**Choice of Initial Antibiotic for ABRS**

No significant differences have been found in clinical outcomes for ABRS among different antibiotic agents. A systematic review and 2 RCTs of sinusitis patients with radiologic or bacteriologic confirmation found no significant difference in rates of clinical resolution for patients treated with amoxicillin or amoxicillin-clavulanate compared with cephalosporins or macrolides. Another review found no differences in 11 comparative meta-analyses but did find a small decrease in failure rates for amoxicillin-clavulanate vs cephalosporins (number needed to treat of 30).

The justification for amoxicillin as first-line therapy for most patients with ABRS relates to its safety, efficacy, low cost, and narrow microbiologic spectrum. Consideration to
prescribing amoxicillin-clavulanate for adults with ABRS is given to those at a high risk of being infected by an organism resistant to amoxicillin. Factors that would prompt clinicians to consider prescribing amoxicillin-clavulanate instead of amoxicillin alone are listed in Table 7.\textsuperscript{123,124}

The use of high-dose amoxicillin with clavulanate (2 g orally twice daily or 90 mg/kg/d orally twice daily) is recommended\textsuperscript{15} for adults with ABRS who are at a high risk of being infected with an amoxicillin-resistant organism. High-dose amoxicillin is preferred over standard-dose amoxicillin primarily to cover penicillin nonsusceptible (PNS) \textit{Streptococcus pneumoniae}. This risk exists in those from geographic regions with high endemic rates (>10%) of invasive PNS \textit{S pneumoniae}, those with severe infection (eg, evidence of systemic toxicity with temperature of 39°C [102°F] or higher, and threat of suppurative complications), age >65 years, recent hospitalization, antibiotic use within the past month, or those who are immunocompromised.\textsuperscript{125}

### Penicillin-Allergic Patients

For penicillin-allergic patients, either doxycycline or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) is recommended as an alternative agent for empiric antimicrobial therapy. Fluoroquinolones, however, are not recommended for first-line therapy of ABRS in patients without penicillin allergy because outcomes are comparable to amoxicillin-clavulanate, and adverse events are higher in some trials.\textsuperscript{126} Combination therapy with clindamycin plus a third-generation oral cephalosporin (cefixime or cefpodoxime) is recommended in adults with a history of non–type I hypersensitivity to penicillin.

Macrolide antibiotics and trimethoprim-sulfamethoxazole are not recommended for initial therapy of ABRS. The high prevalence of macrolide-resistant \textit{S pneumoniae} in the United States (>40%)\textsuperscript{124} and the high rates of resistance to trimethoprim-sulfamethoxazole among both \textit{S pneumoniae} (50%) and \textit{Haemophilus influenzae} (27%) may result in treatment failures,\textsuperscript{127} but this concern has not been substantiated by comparisons in RCTs.

### Duration of Therapy and Adverse Events

Most trials of ABRS administer antibiotic for 10 days. A systematic review of 12 randomized controlled trials with radiologically confirmed ABRS found no difference in clinical success for antibiotics given for 3 to 7 days vs a 6- to 10-day course of therapy.\textsuperscript{128} Similar findings have been noted in other trials, with similar resolution rates up to 3 weeks after treatment regardless of therapy duration.\textsuperscript{48,129-131} When 5 days of antibiotic therapy is compared with 10 days, similar success rates are again observed.\textsuperscript{128} Adverse events are common with antibiotic therapy, but the diverse reporting among studies precludes meaningful comparisons of rates across different antibiotic classes.\textsuperscript{48} An average event rate of 15% to 40% is observed, with the most frequent complaints being nausea, vomiting, diarrhea, abdominal pain, headache, skin rash, photosensitivity, and vaginal moniliasis. Adverse events rarely are of sufficient severity to cause a change in therapy, but the impact of antibiotics on bacterial resistance must also be considered.

Adverse events are more common with antibiotic therapy compared with watchful waiting and are more common with 10 days of therapy compared to shorter courses. Antibiotic therapy increases adverse event rate by, on average, 10% to 12% over placebo,\textsuperscript{112,113} with an odds ratio of 1.8 to 2.1.\textsuperscript{113,115} Conversely, the incidence of adverse events is lower when antibiotics are given for 5 days instead of 10 days (odds ratio, 0.79),\textsuperscript{128} so short courses should be considered for patients with less severe illness.

### Bacteriology of ABRS

The most common bacterial species isolated from the maxillary sinuses of patients with initial episodes of ABRS are

| Table 7. Factors That Would Prompt Clinicians to Consider Prescribing Amoxicillin-Clavulanate Instead of Amoxicillin Alone for Initial Management of Acute Bacterial Rhinosinusitis (ABRS). |
|---|---|
| **Factor** | **Comment** |
| **Situations in which bacterial resistance is likely** | Antibiotic use in the past month  
Close contact with treated individuals, health care providers, or a health care environment  
Failure of prior antibiotic therapy  
Breakthrough infection despite prophylaxis  
Close contact with a child in a daycare facility  
Smoker or smoker in the family  
High prevalence of resistant bacteria in community |
| **Presence of moderate to severe infection** | Moderate to severe symptoms of ABRS  
Protracted symptoms of ABRS  
Frontal or sphenoidal sinusitis  
History of recurrent ABRS |
| **Presence of comorbidity or extremes of life** | Comorbid conditions, including diabetes and chronic cardiac, hepatic, or renal disease  
Immunocompromised patient  
Age older than 65 years |
S pneumoniae, H influenzae, and Moraxella catarrhalis, the latter being more common in children. A review of sinus aspiration studies performed in adults with ABRS suggests that S pneumoniae is isolated in approximately 20% to 43% of aspirates, H influenzae in 22% to 35%, M catarrhalis in 2% to 10%, and Staphylococcus aureus in 10%. Resistance patterns must be considered when prescribing antibiotics for ABRS to avoid using an antibiotic that may be rendered ineffective by bacterial resistance. For example, β-lactamase producing H influenzae has a prevalence of 27% to 43% in the United States and would not be expected to respond to amoxicillin unless clavulanate was added. Similarly, the prevalence of penicillin-resistant S pneumoniae varies geographically, being highest in the Southeast (about 25%) and lowest in the Northwest (about 9%). Last, S aureus, which is found in up to 10% of cases of ABRS, nearly always produces β-lactamase, making it resistant to amoxicillin but not amoxicillin-clavulanate.

The bacteriology of ABRS has changed since immunization with pneumococcal conjugate vaccine (PCV) was introduced in 2000. When patients with ABRS underwent middle meatal culture, the recovery of S pneumoniae decreased (35% postvaccination vs 46% prevaccination), but recovery of H influenzae increased (36% prevaccination vs 43% postvaccination). In addition to a shift in organism prevalence, PCV has decreased the prevalence of invasive S pneumoniae isolates that are penicillin resistant to about 8% to 11%. The introduction of the 13-valent PCV in 2010 may further decrease the prevalence of invasive pneumococcal infections, making it easier to manage pneumococcus as an ABRS pathogen.

**STATEMENT 6. TREATMENT FAILURE FOR ACUTE BACTERIAL RHINOSINUSITIS (ABRS):** If the patient fails to improve with the initial management option by 7 days after diagnosis or worsens during the initial management, the clinician should reassess the patient to confirm ABRS, exclude other causes of illness, and detect complications. If ABRS is confirmed in the patient initially managed with observation, the clinician should begin antibiotic therapy. If the patient was initially managed with an antibiotic, the clinician should change the antibiotic. Recommendation based on randomized controlled trials with limitations supporting a cut-point of 7 days for lack of improvement and expert opinion and first principles for changing therapy with a preponderance of benefit over harm.

**Action Statement Profile**

- Quality improvement opportunity: Define realistic expectations regarding clinical response to initial management and to articulate clearly when reassessment of the patient is warranted
- Aggregate evidence quality: Grade B, randomized controlled trials with limitations supporting a cut-point of 7 days for lack of improvement; Grade D, expert opinion and first principles for changing therapy, including the use of rescue antibiotic in randomized controlled trials
- Level of confidence in evidence: High
- Benefit: Prevent complications, detect misdiagnosis, institute effective therapy
- Risks, harms, costs: Delay of up to 7 days in changing therapy if patient fails to improve; medication cost
- Benefits-harm assessment: Preponderance of benefit over harm
- Value judgments: Avoid excessive classification as treatment failures because of a premature time point for assessing outcomes; emphasize importance of worsening illness in definition of treatment failure
- Intentional vagueness: How to define worsening is left to the judgment of the clinician and patient, but there was group consensus that fluctuations in signs and symptoms within the first 48 to 72 hours of initial therapy were not uncommon and not necessarily indicative of failure.
- Role of patient preferences: None (unless the patient declines reassessment)
- Policy level: Recommendation
- Differences of opinion: None

**Supporting Text**

The purpose of this statement is to emphasize that signs and symptoms of ABRS should generally improve within 7 days of diagnosis, but if they do not improve, or if they worsen at any time, the clinician should reassess the patient. A cut-point of 7 days to define treatment failure can help avoid unnecessary drugs or diagnostic tests caused by prematurely concluding the patient has failed treatment after only a few days, when randomized controlled trials show that improvement may take up to 7 days even when antibiotics are initially prescribed.

**Initial Treatment Failure of Presumed ABRS**

Initial treatment failure of ABRS occurs when the patient worsens or fails to improve with the initial management option by 7 days after diagnosis. Assessing patients who fail initial treatment is important to reaffirm the diagnosis (Table 4), detect complications, exclude other causes of illness, and change management, if necessary. Worsening is defined as progression of presenting signs or symptoms of ABRS or onset of new signs or symptoms. Failure to improve is lack of reduction in presenting signs or symptoms of ABRS by 7 days after diagnosis, which would not apply if the patient had persistent, yet gradually improving, symptoms.
The rationale for using a cut-point of 7 days after initial diagnosis to assess treatment failure for ABRS is based on clinical outcomes in RCTs. A systematic review of ABRS by Rosenfeld and colleagues found that between 7 and 12 days after trial enrollment, 73% of patients randomized to placebo have clinical improvement, rising to 85% when antibiotics are administered. A subsequent Cochrane review had similar findings, with 86% cure or improvement at 7 to 15 days after receiving placebo and 91% after antibiotic therapy.

Defining treatment failure as a lack of clinical improvement within 7 days would result in an acceptable percentage of poor outcomes. Rates of improvement at 3 to 5 days are only 30% for placebo with a nonsignificant rise to 41% for antibiotic. A cut-point of 5 days, therefore, would overdiagnose treatment failure since about two-thirds of patients would not have improved by that time, regardless of initial therapy. Using a stricter criterion of clinical cure (instead of improvement) would result in a failure rate of over 50% at 7 to 12 days. Clinicians and patients must therefore understand that ABRS may take up to 7 days to improve, persistence or minor worsening prior to 7 days does not necessarily indicate treatment failure, and complete cure (absence of all signs and symptoms) may take 14 days or longer.

Patients included in RCTs may not have identical risk factors or illness severity compared with patients not included in (or excluded from) RCTs. Therefore, a 7-day cut-point for improvement may not apply to patients with severe illness, complicated sinusitis, immune deficiency, prior sinus surgery, or coexisting bacterial illness; the clinician should also consider the patient’s age, general health, cardiopulmonary status, and comorbid conditions in determining an appropriate cut-point for assessing treatment failure.

### Assessing the Patient with ABRS Who Fails Initial Treatment

Clinicians should confirm the diagnosis of ABRS by applying the diagnostic criteria in Table 4. If the patient does not have the symptom cluster of “up to 4 weeks purulent nasal drainage . . . accompanied by nasal obstruction, facial pain-pressure-fullness, or both” but instead has individual symptoms, alternate diagnoses should be explored. Migraines, tension headaches, cluster headaches, and temporomandibular joint disorder are common causes of facial pain that can be mistaken for ABRS. Similarly, nasal discharge or congestion can arise from common noninfectious causes that include allergic rhinitis, vasomotor rhinitis, deviated nasal septum, and nasal valve collapse. Imaging studies are not indicated for uncomplicated ABRS but may be appropriate to “rule out” ABRS (eg, a misdiagnosis) if the patient does not respond to therapy.

Patients with a reconfirmed diagnosis of ABRS who fail treatment, especially those with a worsening pattern of illness, should be examined for complications that include orbital or intracranial spread of infection. Suggestive findings on physical examination include proptosis, visual changes, severe headache, abnormal extraocular movements, changes in mental status, and periorbital inflammation, edema, or erythema. Acute frontal sinusitis typically causes severe headache localized to the forehead over the orbits, with tenderness produced by pressure on the floor of the frontal sinus. Sphenoid sinusitis typically causes a dull ache in the back of head, specifically over the occiput with radiation to the frontal and retro-orbital regions.

Culture of nasal secretions may help guide subsequent antibiotic therapy and is best performed by direct sinus aspiration rather than by nasopharyngeal swab. Endoscopically guided cultures of the middle meatus are an alternative in adults. A systematic review by Benninger and colleagues showed that endoscopically directed cultures of the middle meatus had a sensitivity of 81%, specificity of 91%, positive predictive value of 83%, negative predictive value of 89%, and overall accuracy of 87% (95% CI, 81%-93%) compared with direct sinus aspiration.

### Antibiotic Therapy for ABRS Initial Treatment Failures

If the diagnosis of ABRS is confirmed and the treatment failure involves a patient managed initially with observation, the clinician should begin treatment with amoxicillin with or without clavulanate as discussed in the preceding section. For penicillin-allergic patients, either doxycycline or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) is recommended. Combination therapy with clindamycin plus a third-generation oral cephalosporin (cefixime or cefpodoxime) is recommended in adults with a history of non–type I hypersensitivity to penicillin.

Patients who were initially treated with amoxicillin without clavulanate can be treated with high-dose amoxicillin plus clavulanate, doxycycline, a respiratory fluoroquinolone (levofloxacin or moxifloxacin), or the combination of clindamycin plus a third-generation oral cephalosporin (cefixime or cefpodoxime).

If, while on antibiotic therapy, the patient worsens or fails to improve after 7 days, infection with drug-resistant bacteria should be considered and should prompt a switch to alternate antibiotic therapy and reevaluation of the patient. When a change in antibiotic therapy is made, the clinician should consider the limitations in coverage of the initial agent. For example, in patients receiving amoxicillin, it is common to identify a β-lactamase producing *H influenzae* or *M catarrhalis*. Recovery of *S pneumoniae* with reduced susceptibility to β-lactams, macrolides, tetracyclines, and trimethoprim-sulfamethoxazole is also common and has been strongly correlated with previous antibiotic therapy.

Very few studies have investigated the microbiology of treatment failure in ABRS; however, those that cultured sinus material identified a large percentage of bacteria with reduced susceptibility to the original antibiotic. Brook and Gober performed consecutive nasopharyngeal cultures of 20 children with ABRS who failed initial empiric antimicrobial therapy. Enhanced levels of resistance as demonstrated by a minimum inhibitory concentration (MIC) at least 2-fold higher than for the pretreatment isolate was observed in 49% of patients.
The choice of antibiotic for ABRS treatment failure is based on adequate coverage of anticipated bacteria or on antimicrobial sensitivity results if a culture was obtained. Antibiotic exposure increases the likelihood of resistant organisms, such as β-lactam and doxycycline-resistant *S. pneumoniae* and β-lactamase producing *H. influenzae* and *M. catarrhalis*. Predicting the likelihood of adequate antibiotic coverage for resistant organisms is addressed by studies of pharmacokinetics, in vitro susceptibility testing, and minimum inhibitory concentration. Experimental and clinical studies suggest a relationship between treatment outcomes and pharmacodynamic concepts but involve extrapolations from acute otitis media and community-acquired pneumonia.

Optimal therapy of multi-drug-resistant *S. pneumoniae* and β-lactamase producing *H. influenzae* and *M. catarrhalis* would include high-dose amoxicillin-clavulanate (4 g/d amoxicillin equivalent) or a respiratory fluoroquinolone (levofloxacin, moxifloxacin). These agents would also cover less common pathogens, such as *S. aureus* and anaerobic bacteria. Conversely, oral cephalosporins and macrolides are predicted to offer inadequate coverage for *S. pneumoniae* or *H. influenzae*.

**STATEMENT 7A. DIAGNOSIS OF CHRONIC RHINOSINUSITIS (CRS) OR ACUTE RHINOSINUSITIS (ARS): Clinicians should distinguish CRS and recurrent ARS from isolated episodes of acute bacterial rhinosinusitis and other causes of sinonasal symptoms.** Recommendation based on cohort and observational studies with a preponderance of benefit over harm.

**Action Statement Profile**

- **Quality improvement opportunity**: Raise awareness of the distinct clinical entities of CRS and recurrent ARS so that appropriate management strategies may be implemented
- **Aggregate evidence quality**: Grade C, cohort and observational studies
- **Level of confidence in evidence**: High
- **Benefit**: Distinguish conditions that might benefit from additional management strategies than isolated cases of ABRS
- **Risks, harms, costs**: Potential misclassification of illness because of overlapping symptomatology with other illnesses; no cost
- **Benefits-harm assessment**: Preponderance of benefit over harm
- **Value judgments**: Importance of accurate diagnosis
- **Intentional vagueness**: None
- **Role of patient preferences**: Not applicable
- **Exceptions**: None
- **Policy level**: Recommendation
- **Differences of opinion**: None

**Supporting Text**

The purpose of this statement is to improve awareness of the distinct clinical entities of CRS, with and without polyps, and recurrent ARS so that appropriate management strategies may be implemented. These strategies may include additional diagnostic tests, medical therapy, and surgical interventions.

CRS, with and without polyps, and recurrent ARS are temporal- and frequency-based patterns of illness (Table 8) that are distinct from isolated episodes of ABRS. In both diagnoses, the clinical presentation, disease impact, subsequent diagnostic evaluation, and therapy differ significantly from ABRS. Furthermore, because of the chronicity and variety of symptoms that accompany CRS with or without polyps and recurrent ARS, these should be distinguished from other causes of symptoms that are commonly associated with sinonasal disorders.

**CRS with and without Polyps**

Symptoms of CRS vary in severity and prevalence. Nasal obstruction is most common (81%-95%) followed by facial congestion-pressure-fullness (70%-85%), discolored nasal discharge (51%-83%) and hyposmia (61%-69%). The presence of 2 or more signs or symptoms persisting beyond 12 weeks is highly sensitive for diagnosing CRS, but symptom-based criteria alone are relatively nonspecific.

Diagnosing CRS requires that inflammation be documented (polyps, edema, or purulent mucus) in addition to persistent symptoms. Examination of the nasal cavity can be performed using an endoscope or a headlight and nasal speculum, with specific attention to the middle turbinate and middle meatus (Figure 3); an otoscope may also be used but is suboptimal. Edema is often characterized by a boggy or swollen appearance to the mucosa as well as a lighter shade of pink or white mucosa (Figure 4). Inflammation could also manifest with polyps in the nasal cavity or middle meatus (Figure 5). Rarely, CRS may be suspected based primarily on objective findings (eg, nasal polyps or CT imaging) when other conditions have been excluded.

Distinguishing CRS from conditions with similar symptoms can be difficult. Using CT imaging as the criterion standard, the true prevalence of CRS in patients referred for evaluation of potential CRS based on patients’ reported symptoms ranges from 65% to 80%. This prevalence may be lower in primary care settings. CRS may be accompanied by headache, fever, cough, halitosis, fatigue, dental pain, and other nonspecific signs or symptoms. Therefore, the differential diagnosis of CRS includes allergic rhinitis, nonallergic rhinitis, vasomotor rhinitis, eosinophilic nonallergic rhinitis, nasal septal deformity, and nonrhinogenic causes of facial pain. The latter include neurologic disorders, such as vascular headaches, migraine, cluster headache, trigeminal neuralgia, and other facial pain syndromes.

CRS is primarily an inflammatory disease, with occasional exacerbations (ABRS) associated with infection. Treating the episodic infections alone leaves the underlying condition untreated, likely contributing to an increased frequency of exacerbations. In this way, CRS is very similar to chronic bronchitis. CRS is associated with sinus edema and impaired mucociliary clearance. With edema-related obstruction and retained mucus, bacterial infection can more easily set up.
Therefore, when CRS is present, it should be treated with medications and other therapies that will target the underlying inflammatory disorder.

**Recurrent Acute Rhinosinusitis**

Recurrent acute rhinosinusitis is diagnosed when 4 or more episodes of ABRS occur in the past 12 months without signs or symptoms of rhinosinusitis between episodes. Although recognized as a distinct form of rhinosinusitis, only a few cohort studies have documented the characteristics and clinical impact of recurrent acute rhinosinusitis. The frequency cutoff for a minimum number of episodes to be considered for the diagnosis of recurrent acute rhinosinusitis from a multidisciplinary panel has reaffirmed a minimum cutoff of 4 or more episodes per year of ABRS.

The proper diagnosis of recurrent ARS requires that each episode meets the criteria for ABRS (Table 4). Confirming a true bacterial episode of rhinosinusitis is desirable, but not essential, for substantiating an underlying diagnosis of recurrent ARS. In such cases, examination of the patient during an episode of ABRS (among the 4 episodes occurring per year) is necessary to
corroborate the diagnosis. Examination of the middle meatus for purulence in the decongested state may strongly suggest ABRS and allows endoscopically guided culture.

ARS should be distinguished from isolated ABRS because of a greater disease burden, diagnostic approach, and approach to management. The symptom burden of recurrent ARS is similar to CRS, but antibiotic utilization is higher. Patients with both conditions may benefit from nasal culture or imaging studies. Neither chronic antibiotic therapy nor nasal steroids have demonstrated benefit in reducing episodes of recurrent acute sinusitis. An allergy-immunology evaluation may be considered to detect coexisting allergic rhinitis or an underlying immunologic deficiency. Sinus surgery may be considered in patients with recurrent ARS.

STATEMENT 7B. OBJECTIVE CONFIRMATION OF A DIAGNOSIS OF CHRONIC RHINOSinusITIS (CRS): The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over harm.

Action Statement Profile
- Quality improvement opportunity: Reduce overdiagnosis of CRS based on self-reported symptoms
- Aggregate evidence quality: B, cross-sectional studies
- Level of confidence in evidence: High
- Benefit: Improved diagnostic certainty for CRS and fewer false-positive diagnoses, which allows patients with CRS to be managed more promptly and those without CRS to seek additional evaluation of their sinusitis-like symptoms and institute effective therapy
- Risks, harms, costs: None associated with improved diagnostic certainty, but diagnostic modalities have their own risk and direct cost profiles
- Benefits-harm assessment: Preponderance of benefit over harm
- Value judgments: Strong consensus by the GUG that the need for objective documentation of sinonasal inflammation is likely underappreciated and underperformed, despite its critical role in substantiating a diagnosis of CRS
- Intentional vagueness: Which of the three listed diagnostic modalities to use is not stated
- Role of patient preferences: Large role for shared decision making with clinicians regarding choice of the confirmatory diagnostic modality
- Exceptions: None
- Policy level: Strong recommendation
- Differences of opinion: None

Supporting Text
The purpose of this statement is to strongly emphasize that a diagnosis of CRS cannot be based on signs and symptoms alone but also requires objective evidence of sinonasal inflammation (Table 8). Requiring objective signs of inflammation increases diagnostic accuracy for CRS and serves to limit overdiagnosis. Moreover, objective confirmation of inflammation will prevent unnecessary tests and interventions for individuals with self-reported sinonasal symptoms that can be readily mistaken for CRS, such as those caused by perennial allergic rhinitis.
Objective confirmation of sinonasal inflammation may be made by direct visualization or by CT scanning. Direct visualization is best accomplished with nasal endoscopy, but in some patients, anterior rhinoscopy using an otoscope or nasal speculum may suffice. An important part of direct visualization is identification of nasal polyps, as that will lead the clinician to rule out neoplasm in unilateral polyps, as well as suggest slightly different treatment strategies for bilateral polyps.

Patient preference does influence the choice of confirmatory modality. Anterior rhinoscopy has the least cost and procedural risk but is less sensitive than endoscopy and increases the chance of misdiagnosis. Nasal endoscopy and CT scanning both have a much higher diagnostic accuracy, but CT scanning includes the small associated risk of radiation exposure, while nasal endoscopy includes an added cost. These differences are summarized in Table 9 and discussed further below.

**Direct Visualization by Endoscopy or Anterior Rhinoscopy**

Direct visualization of the sinonasal mucosa at its most refined state is performed by nasal endoscopy. Endoscopic evaluation is generally an office procedure used to evaluate the inflammatory status of the sinonasal mucosa and to assess nasal masses or lesions that are noted on physical examination. Nasal endoscopy can be performed with a flexible or rigid endoscope, typically after a topical decongestant and anesthetic are applied to the nasal mucosa. Areas visualized during endoscopy include the nasal cavity, inferior turbinate, middle meatus, uncinate process, hiatus semilunaris, maxillary ostia, anterior ethmoidal bulla, nasofrontal recess, sphenoid recess, sphenoid ostium, and the nasopharynx.

Findings on nasal endoscopy that support a diagnosis of CRS include purulent mucus or edema in the middle meatus or ethmoid region, or polyps in the nasal cavity or middle meatus. Examples include abnormalities directly related to CRS or recurrent acute rhinosinusitis, such as nasal polyps, purulent nasal discharge, and septal deviation. Alternative findings that may suggest a more complicated or different disease process include neoplasms, soft tissue masses, foreign objects, tissue necrosis, and findings consistent with autoimmune or granulomatous disease.

A systematic review assessed the diagnostic value of nasal endoscopy for adults with suspected CRS, using CT imaging as the gold standard for diagnostic certainty. Compared with baseline risk for CRS, a positive nasal endoscopy (pus or polyps) had an added value for confirming CRS of 25% to 28%, and a negative nasal endoscopy had an added value of ruling out CRS of 5% to 30%. The authors concluded that nasal endoscopy should be a first-line confirmatory test for CRS, reserving CT scanning for patients with a prolonged or complicated clinical course.

Anterior rhinoscopy allows visualization of the anterior one-third of the nasal cavity with direct illumination and a speculum or other instrument to dilate the nasal vestibule. In the primary care setting, an otoscope is often used to examine the nasal cavity. In cases of large polyps or gross purulence, anterior rhinoscopy is sufficient; however, nasal endoscopy is superior in that it also allows visualization of the posterior nasal cavity, nasopharynx, and often the sinus drainage pathways in the middle meatus and superior meatus. Advantages of nasal endoscopy over anterior rhinoscopy are the ability to identify posterior septal deviation, polyps or secretions in the posterior nasal cavity, and polyps or secretions within the middle meatus or in the sphenoidoidal recess. Furthermore, nasal endoscopy allows directed aspiration of abnormal secretions for analysis and culture.

**CT Imaging**

A diagnosis may also be confirmed by CT scanning or magnetic resonance imaging (MRI). MRI for confirmation of diagnosis is discouraged because of increased cost and hypersensitivity (overdiagnosis) in comparison to CT without contrast.

CT scanning can help quantify the extent of inflammatory disease based on opacification of the paranasal sinuses and improves diagnostic accuracy because CT imaging findings correlate with the presence or absence of CRS in patients with suggestive clinical symptoms. Although CT findings do not necessarily correlate with symptom severity, they offer an objective method for monitoring recurrent or chronic disease. Mucosal abnormalities, sinus ostial obstruction, anatomic variants, and sinonasal polyposis are best displayed on CT. The appearance of the mucosa, however, is nonspecific, and mucosal thickening should be interpreted in the context of clinical examination, nasal endoscopy, or both.

An important role of CT imaging in CRS with or without polyps is to exclude aggressive infections or neoplastic disease that might mimic CRS or ARS. Osseous destruction, extra-sinus extension of the disease process, and local invasion suggest neoplasia. If any such findings are noted, MRI should be performed to differentiate benign obstructed secretions from tumor and to assess for spread outside the nasal cavity and sinuses.

CT of the paranasal sinuses should be obtained when endoscopic sinus surgery is considered or planned in patients with

---

**Table 9. Comparison of Modalities for Objective Confirmation of Sinonasal Inflammation.**

<table>
<thead>
<tr>
<th>Modality</th>
<th>Method</th>
<th>Cost</th>
<th>Discomfort</th>
<th>Risk</th>
<th>Sensitivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasal endoscopy</td>
<td>Direct visualization</td>
<td>Moderate</td>
<td>Minimal to moderate</td>
<td>Minimal</td>
<td>Good</td>
</tr>
<tr>
<td>Anterior rhinoscopy</td>
<td>Direct visualization</td>
<td>Minimal</td>
<td>Minimal</td>
<td>Minimal</td>
<td>Fair</td>
</tr>
<tr>
<td>Computed tomography</td>
<td>Radiographic</td>
<td>High</td>
<td>Minimal</td>
<td>Radiation exposure</td>
<td>Excellent</td>
</tr>
</tbody>
</table>

*Ability to detect signs of inflammation if present in the nasal cavity or sinuses.*
CRS or recurrent ARS. In addition to demonstrating abnormal mucosa and opacified sinuses, the study will provide the anatomic detail necessary to guide the surgery. CT imaging of the paranasal sinuses has traditionally involved direct axial and coronal images to adequately visualize the ostiomeatal complex. Multidetector CT is a newer technology that offers advantages over single-detector imaging of the paranasal sinuses, because the patient is scanned once and all other planes (eg, coronal, sagittal) are reconstructed from the original data set. Multidetector CT imaging may reduce total radiation dose to the patient, and in the setting of nonneoplastic evaluation, it is acceptable to use not only for diagnosis but also for surgical intervention.

**STATEMENT 8. MODIFYING FACTORS:** Clinicians should assess the patient with chronic rhinosinusitis or recurrent acute rhinosinusitis for multiple chronic conditions that would modify management such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia. Recommendation based on one systematic review and multiple observational studies with a preponderance of benefit over harm.

**Action Statement Profile**

- Quality improvement opportunity: Identify comorbid conditions that are known to accompany CRS and recurrent ARS, the knowledge of which would improve management of the sinusitis, and conversely, management of sinusitis may improve the associated chronic condition (asthma)
- Aggregate evidence quality: Grade B, one systematic review and multiple observational studies
- Level of confidence in evidence: Medium
- Benefit: Identify modifying factors that would alter management of CRS or recurrent acute rhinosinusitis; identify conditions that require therapy independent of rhinosinusitis
- Risks, harms, costs: Identifying and treating incidental findings or subclinical conditions that might not require independent therapy; morbidity related to specific tests; variable costs based on testing ordered
- Benefits-harm assessment: Preponderance of benefit over harm
- Value judgments: Consensus that identifying and managing modifying factors will improve outcomes
- Intentional vagueness: The method of assessing for these conditions is at the discretion of the clinician and may include history, physical examination, or diagnostic tests.
- Role of patient preferences: Small
- Exceptions: None
- Policy level: Recommendation
- Differences of opinion: None

**Supporting Text**

The purpose of this statement is to make clinicians aware of the benefit of diagnosing and treating underlying conditions associated with CRS, so as to improve clinical outcomes. In contrast to ABRS, CRS and recurrent ARS have potential predisposing factors that may contribute to illness persistence, recurrence, or both. Asthma, cystic fibrosis, immunocompromised state, ciliary dyskinesia, and anatomic variation are some factors that have been investigated in this regard. Ideally, early identification of factors contributing to the recurrence or persistence of rhinosinusitis could play a crucial role in selecting the most appropriate treatment for individual patients.

The obligation to “assess” the patient for asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia is fulfilled by documenting in the medical record that these conditions were considered in the differential diagnosis of CRS or recurrent ARS. Further assessment may include history, physical examination, or diagnostic tests at the discretion of the clinician. The guideline development group recognizes that except for asthma, these conditions are rare, and does not recommend a “shotgun” approach to extensive, nontargeted testing for all patients. Rather, testing should be individualized based on the patient’s history and physical examination.

**Asthma and Rhinosinusitis**

The association between rhinosinusitis and asthma is supported by the high prevalence of CRS and recurrent ARS in asthmatics and is most noticeable when the asthma is severe. Asthma severity has a direct correlation with the severity of radiographic sinus disease, and 84% to 100% of patients with severe asthma have abnormal sinus CT scan findings. Moreover, when CRS is treated (medically or surgically), asthma symptoms improve and the need for asthma-related medications decreases.

A systematic review found that endoscopic sinus surgery improves asthma control while decreasing asthma exacerbations, hospitalizations, and use of systemic and inhaled corticosteroids; pulmonary function, however, is unchanged. These findings suggest a benefit of prompt therapy for CRS in asthmatics if rhinosinusitis is considered a reason for poor asthma control. Similarly, asthmatics with difficult to control illness should be assessed for unsuspected rhinosinusitis, with CT scanning or nasal endoscopy, since the signs and symptoms of CRS may be subtle and overlooked if not specifically sought.

**Cystic Fibrosis and Rhinosinusitis**

The association between cystic fibrosis (CF) and CRS has long been recognized, with CRS reported in 30% to 67% of patients with CF over all age groups. Symptoms of CRS are reported by 36% of obligate carriers of a cystic fibrosis gene mutation, compared with an estimated background prevalence of CRS between 13% and 14%. The association of CF mutation and CRS has been assessed in different fashions and within different populations, sometimes yielding conflicting results. In Finland, where the reported incidence of mutation carriage is about 1:80, only 1:127 patients with CRS screened for ΔF508 and 394delIT revealed the presence of a cystic fibrosis mutation. It is well...
documented, however, that concordance exists between microorganisms isolated in the upper and lower airways of CF patients with CRS, and upper airway colonization may precede spread of these bacteria to the lower airways.195-198

Multiple observational studies show that using a more aggressive treatment paradigm for CF patients with CRS, with regard to both maximizing surgery as well as postoperative medical therapy, can have a beneficial effect on the course of the sinus disease.199-202 Since CRS or recurrent ARS, especially if associated with nasal polyps, can be the first manifestation of CF, patients with polyps who present before age 18 years or have refractory rhinosinusitis should be screened for underlying CF.

**Immunodeficiency and Rhinosinusitis**

Several immunodeficient states have been documented in patients with CRS or recurrent acute rhinosinusitis,203-205 supporting the role of immunological testing when evaluating patients with refractory or recurrent disease.206 Common immunodeficiencies identified include decreases in serum IgA and IgG and abnormalities in IgG functional response to polysaccharide vaccines.203-206 See Key Action Statement 9 in this clinical practice guideline for more details on appropriate testing to evaluate for this small, yet important, group of patients.

**Ciliary Dyskinesia and Rhinosinusitis**

Ciliary dyskinesia accounts for a small percentage of patients with CRS demonstrating decreased mucociliary clearance.207-210 Even in patients without an underlying genetic disorder causing ciliary dyskinesia, the normal mucociliary transit time (MTT) of 10 to 14 minutes is prolonged significantly when CRS is present.209 Increased MTT has been identified in a growing number of patients with human immunodeficiency virus and has been implicated in this population’s increased risk of recurrent rhinosinusitis.210

Not all studies, however, support the role of decreased mucociliary function in the pathogenesis of CRS. Ciliary beat frequency in mucosa from the nose and paranasal sinuses of patients with CRS showed no difference compared with normal controls, and frequency was increased in specimens recovered from patients with nasal polyps.208 Similar to CF and immunologic testing, ciliary dyskinesia testing may be indicated when patients have intractable rhinosinusitis, especially when accompanied by frequent or prolonged lower respiratory infections. Patients with CF and CRS may benefit from endoscopic sinus surgery, especially when obstructing nasal polyps are present, but relapse is common and revision surgery is often required.

**Other Considerations**

Early research on the pathogenesis of CRS and recurrent ARS focused on anatomic abnormalities,211-214 which could obstruct the paranasal sinuses and trigger infection.215-216 Based on this assumption, descriptions of anatomic relationships, variances, associations with adjacent anatomic regions, and the importance of accurate radiographic data on surgical planning and intervention have populated the early endoscopic literature.174,217-221 Nonetheless, evidence is lacking regarding a causal relationship between anatomic abnormalities and chronic disease. One study180 has correlated recurrent ARS with anatomic abnormalities in the anterior ethmoid sinus.

The relationship between gastroesophageal reflux disease (GERD) and rhinosinusitis is unclear, although there is an increasing body of literature suggesting a direct or indirect link. High-level evidence, however, to support this relationship is lacking. Most of the studies that suggest an association are small case series.222-224 For example, in one small study,225 95% of patients with medically and surgically refractory rhinosinusitis had a positive pharyngeal pH probe, but nasopharyngeal pH did not correlate with pH in the pharynx. One mechanism by which GERD may cause sinonasal symptoms is through a nasal-esophageal reflex. Wong and colleagues226 instilled hydrochloric acid and saline at the gastroesophageal junction and described a vagal reflex causing increased nasal mucus production and symptom scores.

Vaezi and colleagues227 found that proton pump inhibitors significantly reduced symptoms of postnasal discharge in patients with rhinitis compared with placebo. Although there are no placebo-controlled studies that show a direct benefit of treating GERD on rhinosinusitis, these 2 conditions often coexist and share similar symptoms. Patients with clinically significant GERD should be managed accordingly, but whether treating mild or subclinical GERD can affect rhinosinusitis is unknown.
• Intentional vagueness: The methods and scope of testing for allergy and immune function are at the discretion of the clinician
• Role of patient preferences: Large for shared decision making
• Exceptions: None
• Policy level: Option
• Differences of opinion: None

Supporting Text

The purpose of this statement is to describe the role of testing for allergy and immune function in patients with CRS or recurrent ARS, emphasizing that testing is optional because there is no substantive evidence to support a consistent beneficial effect of treatment despite the high prevalence of allergy in patients with rhinosinusitis.

Testing for Allergy

The prevalence of allergic rhinitis (AR) is 40% to 84% in adults with CRS \(^{228-230}\) and 25% to 31% in young adults with acute maxillary sinusitis. \(^{231,232}\) About twice as many patients with allergic rhinitis, compared with normal subjects, have abnormal CT scans. \(^{233}\) Extensive sinus disease, as quantified by sinus CT imaging, is associated with allergy in 78% of patients and asthma in 71%. \(^{234,235}\) Patients with both allergy and CRS are more symptomatic than nonallergic patients with similar CT findings. \(^{236,237}\) In one study of 200 patients with CRS, more than half had allergic rhinitis, which was considered the most important underlying cause of sinusitis. \(^{238}\)

Edema caused by allergic rhinitis may obstruct the paranasal sinuses, \(^{239}\) and this concept is supported by a higher prevalence of mucoperiosteal disease on CT imaging in patients with allergies compared to others without. \(^{235,236}\) Furthermore, a hyperresponsive state associated with allergic rhinitis may increase susceptibility to inflammation within the nose and paranasal sinuses, thereby predisposing to rhinosinusitis. \(^{239}\) A recent retrospective cohort study of CRS determined AR as a premorbid factor in newly diagnosed CRS. \(^{240}\) Of note, most of the above studies are case series with heterogeneous inclusion criteria that suggest a link between these allergy and rhinosinusitis conditions but do not imply causality.

A systematic review by Wilson and colleagues \(^{241}\) concluded that allergy testing is an option for patients with CRS or recurrent ARS. Allergy skin tests are the preferred method for detecting IgE-mediated sensitivity. For most allergens, in vitro allergen-specific immunoassays detect IgE-specific antibody in the serum of most, but not all, patients who respond clinically to those allergens. The sensitivity of immunoassay compared with prick or puncture skin tests ranges from 50% to 90%, with an average of 70-75% for most studies. \(^{242}\) A direct correlation for clinical disease cannot be assumed by evidence provided from skin testing or in vitro allergen-specific immunoassays unless results are interpreted by a qualified clinician based on history and physical examination obtained on face-to-face contact with the patient.

If allergy testing is positive and appears clinically relevant based on individual assessment, management may include environmental control measures, pharmacologic therapy, or immunotherapy as an immunomodulating approach. There are, however, limited data to support that allergen avoidance and/or immunotherapy improves CRS or recurrent ARS \(^{19,47}\) and the level of evidence for existing research is poor. \(^{241}\) Although allergic rhinitis can prolong the course of ABRS, the clinical impact is small (6%-8% increased risk) and does not support different management of ABRS patients with or without underlying allergy. \(^{17}\)

Testing for Immune Function

Immunodeficiency should be considered in patients with CRS or recurrent ARS when aggressive management has failed or when sinusitis is associated with otitis media, bronchiectasis, or pneumonia. \(^{203,205}\) Sinusitis was one of the most frequent presenting infections in the French national study of primary hypogammaglobulinemia, and 36% of patients with common variable immunodeficiency (CVID) had sinusitis. \(^{241}\) Another study of patients with radiographically diagnosed sinusitis refractory to medical and surgical therapy revealed 10% of patients to have CVID and 6% to have IgA deficiency. \(^{203}\) Patients failing medical therapy and undergoing sinus surgery have been noted (11%) to have specific antibody deficiency. \(^{206}\) CRS or recurrent ARS can affect 30% to 68% of patients with human immunodeficiency virus (HIV) infection. \(^{244}\)

The most common primary immunodeficiency disorders associated with CRS or recurrent ARS are humoral immunodeficiencies, such as selective IgA deficiency, common variable immunodeficiency, and specific antibody deficiency, which features normal IgG levels but a defective response to polysaccharide vaccines. \(^{245}\) Laboratory studies in patients with CRS or recurrent ARS may include quantitative immunoglobulin measurements (IgG, IgA, and IgM), preimmunization- and postimmunization-specific antibody responses to tetanus toxoid and pneumococcal polysaccharide vaccines, CH50, and measurement of T-cell number and function (delayed hypersensitivity skin tests and flow cytometric enumeration of T cells). IgG subclasses should not be checked routinely in immunodeficiency evaluation as the connection of IgG subclass deficiency to recurrent or CRS is controversial, and the clinical significance of abnormal IgG subclasses in patients with recurrent infections is unclear. \(^{246}\)

STATEMENT 10. CHRONIC RHINOSINUSITIS (CRS) WITH POLYPS: The clinician should confirm the presence or absence of nasal polyps in a patient with CRS. Recommendation based on observational studies with preponderance of benefit over harm.

Action Statement Profile

• Quality improvement opportunity: Improve awareness of the prevalence of polyps in patients with CRS and their role as a modifying factor for further diagnostic assessment and treatment.
• Aggregate evidence quality: High; Grade A, systematic review of multiple RCTs

Downloaded from oto.sagepub.com at Mahidol University on April 1, 2015
Standing nasal polyps and a history of previous surgeries are potential risk factors for CRS with nasal polyps. The integrity of the orbit and cranial vault. Patients with long-standing nasal polyps and a history of previous surgeries are likely to have significant anatomical changes within the paranasal sinuses.

Unilateral nasal polyps may be a sign of CRS but are less common than bilateral polyps and should prompt investigation for other conditions that can mimic CRS, including carcinoma, inverting papilloma, antrochoanal polyp, or allergic fungal sinusitis. These conditions will require a more thorough diagnostic evaluation and treatment than suggested for bilateral nasal polyps associated with CRS. Tissue biopsy is required to make the diagnosis of nasal polyp and to rule out other pathologies; scraping of nasal polyps is not recommended. Testing for allergy or immune function in CRS is an option that is unaltered by the presence, or absence of polyps, and additional details can be found in the preceding key action statement (Key Action Statement 9).

Chronic topical or intravenous antibiotics for CRS with nasal polyps is not recommended, but select oral antibiotics, especially the macrolide class, may be beneficial because of their anti-inflammatory effects. Conversely, topical nasal steroid sprays are indicated for long-term treatment of nasal polyps in the setting of CRS. If no response is seen within 3 months, a short course of oral corticosteroids is reasonable to try. Off-label topical corticosteroids in the nasal cavity, including budesonide, may also be beneficial.

### Supporting Text

The purpose of this statement is to encourage clinicians to assess for nasal polyps in a patient with CRS, because nasal polyps will likely affect the utility of additional diagnostic testing and treatment management.

The exact prevalence of nasal polyps in rhinosinusitis is unknown, but about 4% of patients with CRS have concurrent polyps. An association between asthma, nasal polyps, and aspirin sensitivity was recognized many years ago, but, conversely, nasal polyps do not seem to be related to allergic rhinitis. The prevalence of nasal polyps likely varies by geography and environment, although large studies of the prevalence of polyps across different geographic areas are lacking.

Identifying nasal polyps requires careful examination of the nasal airway. Large polyps, which obstruct the nasal cavity, are easily visualized with a nasal speculum or handheld otoscope. Small nasal polyps in the middle meatus or in the posterior nasal cavity, however, may only be detected by nasal endoscopy. A clinician who suspects nasal polyps in a patient with CRS and is unable to perform nasal endoscopy should refer the patient to a physician who can thoroughly examine the nasal cavity.

CT imaging of the sinuses is often useful in evaluating CRS with nasal polyps, especially for unilateral polyps, concern for polyps extending outside of the nasal cavity, or other atypical presentations. CT examination defines the extent of involvement of nasal polyps throughout the nasal cavity, the status of bony landmarks (ie, lamina papyracea), and the integrity of the orbit and cranial vault. Patients with long-standing nasal polyps and a history of previous surgeries are

---

### STATEMENT 11. TOPICAL INTRANASAL THERAPY FOR CHRONIC RHINOSINUSITIS (CRS): Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS. Recommendation based on a preponderance of benefit over harm.

### Action Statement Profile

- **Quality improvement opportunity:** Address underutilization; promote awareness of efficacy; reduce confusion over delivery method, frequency, and duration; educate patients on optimal administration
- **Aggregate evidence quality:** Grade A, systematic reviews of RCTs
- **Level of confidence in evidence:** High
- **Benefit:** Symptomatic relief, promoting awareness of effective over-the-counter interventions, discouraging improper and ineffective usage, and avoiding adverse events from systemic therapies
- **Risks, harms, costs:** Intranasal discomfort, burning, stinging; epistaxis; direct costs of saline or steroid
- **Benefits-harm assessment:** Preponderance of benefit over harm
- **Value judgments:** None
- **Intentional vagueness:** The choice of saline, steroid, or both is a shared decision; it is not clear how long the treatment should last as the natural history is unknown
- **Role of patient preferences:** Large role for deciding which products to use and their duration
- **Exceptions:** None
Costs of nasal irrigation vary but are generally low, however, are expensive compared with homemade solutions over the counter may make it easier for the patients to perform nasal irrigation. Commercially available preparations, however, are expensive compared with homemade solutions. Costs of nasal irrigation vary but are generally low, especially when patients are instructed to make their own solution. Recipes for preparation of homemade solutions and delivery methods vary widely (pot, pulsatile irrigation, atomizer, bulb/syringe, squeeze bottle, and low-pressure irrigation [Neti pot]).

### Table 10. Patient Instructions for Optimal Use of Topical Nasal Steroid.a

1. Shake the bottle well.
2. Look down by bending your neck and looking toward the floor.
3. Put the nozzle just inside your nose using your right hand for the left nostril and your left hand for the right nostril.
4. Aim toward the outer wall and squirt once or twice as directed; do not aim toward the nasal septum (in the middle of the nose) to prevent irritation and bleeding.
5. Change hands and repeat for other side.
6. Do not sniff hard.

*aAdapted from Scadding and colleagues.*272

- Policy level: Recommendation
- Differences of opinion: None

### Supporting Text

The purpose of this statement is to highlight the importance of intranasal saline and intranasal corticosteroid therapy in providing symptomatic relief and improved quality of life for patients with CRS. Despite the benefits of these interventions seen in RCTs and systematic reviews, the GUG felt they were underused by clinicians managing patients with CRS.

### Saline Irrigation for CRS

The beneficial effects of saline in improving symptoms and quality of life include improvement in mucous clearance, enhanced ciliary activity, disruption and removal of antigens, biofilms and inflammatory mediators, and direct protection of the sinonasal mucosa. Nasal saline irrigation has been recommended by clinicians both as adjunctive therapy for chronic sinusosal symptoms and in the postoperative period to moisten and cleanse sinonasal clots and crust, as well as to promote mucosal healing.

A beneficial effect of nasal irrigation for symptomatic relief of CRS has been shown in a Cochrane review and in other systematic reviews.258,265 Nasal saline irrigation is effective as sole treatment for CRS or as an adjunct to topical nasal steroids, but compared directly with topical nasal steroids, the benefits of saline irrigation are less pronounced.264 The safety and minimal side effects of saline irrigation, however, make it an attractive sole therapy for CRS. Common side effects of nasal irrigation include fluid dripping from the nose.

Clinicians should not confuse saline spray with saline irrigation, because irrigation is more effective in expelling secretions and improving quality of life.265,266 Irrigation can be performed with isotonic or hypertonic nasal solution, but evidence is insufficient to support superiority of either approach.265 In addition, the optimal frequency or method of irrigation is uncertain.264 This uncertainty, combined with the time commitment required for regular saline irrigation, may explain underuse despite well-established efficacy in relieving CRS symptoms.

Availability of delivery devices and ready-made saline solutions over the counter may make it easier for the patients to perform nasal irrigation. Commercially available preparations, however, are expensive compared with homemade solutions. Costs of nasal irrigation vary but are generally low, especially when patients are instructed to make their own solution. Recipes for preparation of homemade solutions and delivery methods vary widely (pot, pulsatile irrigation, atomizer, bulb/syringe, squeeze bottle, and low-pressure irrigation [Neti pot]).

### Topical Intranasal Steroids

Inflammation is considered the pathological basis for CRS, and therefore corticosteroids are widely recommended. Corticosteroids are effective as anti-inflammatory agents due to their actions on reducing proinflammatory and increasing anti-inflammatory gene transcription, reducing airway inflammatory cell infiltration, and suppressing proinflammatory mediators, cell chemotactic factors, and adhesion molecules.269

The efficacy of topical steroid therapy for reducing symptoms of CRS is supported by systematic reviews of randomized controlled trials from Cochrane authors and others that show benefits with excellent safety and minimal adverse events. In some reviews, however, subgroup analyses show benefits of topical steroids for CRS with polyps but absent or unknown efficacy for CRS without associated polyps.256,258 Classes of topical steroids include first-generation intranasal steroids such as beclomethasone dipropionate, triamcinolone acetonide, flunisolide, and budesonide and newer preparations, such as fluticasone propionate, mometasone furoate, ciclesonide and fluticasone furoate.

Topical nasal steroids are most effective when properly administered. Since patients may not be familiar with the optimal method for using the medication, we recommend that clinicians describe or demonstrate how to properly administer a nasal steroid. Patient-friendly instructions are summarized in Table 10 and may assist in this educational process.

Adverse events of topical nasal steroids are generally minor (epistaxis, headache, and nasal itching), but when steroids are used for long-term control of CRS, additional concerns arise regarding systemic absorption and ocular effects. Long-term use, however, has not been shown to affect systemic cortisol levels or to increase the risk of lens opacity, elevated intraocular pressure, or any other ocular symptoms.274 Patients on long-term topical nasal steroids should consult their physicians to determine if regular ophthalmic monitoring is appropriate.

The GUG agreed, based on expert consensus, that topical nasal steroids should be used for at least 8 to 12 weeks because of the time needed for symptomatic relief and to assess benefit to the patient. Moreover, there was strong agreement that
patients may not know how to best deliver steroid to the nasal cavity and should therefore be given specific instructions on how to use the medication. The GUG felt that no statement can be made regarding a specific length of treatment and that decisions should be individualized based on the degree of symptom relief, patient preference, and clinician experience.

**STATEMENT 12. ANTIFUNGAL THERAPY FOR CHRONIC RHINOSINUSITIS (CRS). Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS. Recommendation (against therapy) based on systematic review of RCTs with a preponderance of benefit over harm (for not treating).**

**Action Statement Profile**
- Quality improvement opportunity: Discourage use of antifungal therapy for CRS based on lack of efficacy and presence of significant cost and adverse effects
- Aggregate evidence quality: Grade A, systematic reviews of RCTs
- Level of confidence in evidence: High
- Benefit: Avoid cost of ineffective medications, avoid unnecessary adverse events, direct management away from ineffective therapy to beneficial therapy (opportunity cost), avoid selection of resistant fungi and alterations of sinonasal flora
- Risks, harms, costs: None (for avoiding ineffective therapy)
- Benefits-harm assessment: Preponderance of benefit over harm (for not treating)
- Value judgments: Antifungal therapy is frequently used, with regional variations, for treating CRS despite good evidence of no efficacy
- Intentional vagueness: None
- Role of patient preferences: None
- Exceptions: Patients with allergic fungal sinusitis or invasive fungal sinusitis
- Policy level: Recommendation
- Differences of opinion: None

**Supporting Text**

The purpose of this statement is to emphasize that clinicians should not prescribe systemic or topical antifungal therapy for patients with CRS because of potential adverse events that are not offset by consistent, significant benefits in systematic reviews from Cochrane275 or other investigators.255,258,271,276

Despite a lack of efficacy, antifungal therapy for CRS is used widely by some clinicians with regional variations. Our main intent with this key action statement, therefore, is to educate patients and clinicians and to prevent antifungal therapy for CRS. This statement, however, does not apply to antifungals for invasive fungal sinusitis or to allergic fungal sinusitis, for which more evidence is needed to make any definitive conclusions.

**Role of Fungi in CRS**

Ponikau and colleagues277 first described eosinophilic infiltrates within the mucosa in patients with CRS, suggesting a possible role of fungus in these patients. This was bolstered by prior studies demonstrating fungi in the surgical specimens of patients with CRS,278-280 leading to a hypothesis that patients with CRS have a distinctive immune response to ubiquitous fungi compared with normal control patients, involving a noninvasive, nonallergic interleukin 5–mediated response and eosinophilic inflammation.281,282 This was the beginning of a continuing debate about how applicable this theory is to the general population of patients with CRS and how antifungal therapy might affect them.

Every systematic review that was limited to RCTs245,258,275 concluded that there was no beneficial effect from either oral or topical antifungal therapy in CRS. The only potential benefits of oral antifungal therapies were found in a systematic review of observational studies with nonvalidated outcome measures,281 which carry a risk of bias that makes conclusions impossible. In the Cochrane review,275 which included both oral and topical antifungals and had strict inclusion criteria, there was no evidence of benefit for topical antifungals. Only 1 of 5 trials reported benefit for radiographic and endoscopic scores (not symptom scores) and no benefit of systemic antifungal therapy over placebo for the same outcomes.

Adverse effects of these therapies have been documented, including elevated liver function tests for oral antifungals, nasal irritation, decreased sinonasal-related quality of life, decreased ciliary function at increasing concentrations, and extremely high cost for topical antifungals.275,283,284 There is also the potential for inducing fungal resistance due to the low concentrations used in topical formulations. Multiple trials used concentrations of amphotericin B at 100 µg/mL, a concentration that has been documented to not impede fungal growth in vitro compared with true inhibition at 200 and 300 µg/mL.285 There is also the opportunity cost to patients, who may receive these treatments in the place of other management strategies with known benefit.

**Implementation Considerations**

The complete guideline is published as a supplement to Otolaryngology–Head and Neck Surgery, and an executive summary will be simultaneously published in the main journal. A full-text version of the guideline will also be accessible free of charge at the www.entnet.org, the AAO-HNSF website. The guideline will be presented to AAO-HNSF members as a miniseminar at the annual meeting following publication. Existing brochures, publications, and patient information sheets from the AAO-HNSF will be updated to reflect the guideline recommendations.

An anticipated barrier to the diagnosis of rhinosinusitis is the differentiation of VRS from ABRS in a busy clinical setting. This is facilitated by the clear, unambiguous criteria in Table 4 and in Key Action Statement 1a, which allow clinicians to identify illness that is likely bacterial based on the history and time course of illness, without invasive tests or imaging studies. Use of these criteria may be assisted by a teaching card or visual aid. Patient education (Table 5) may help address this barrier. When diagnosed with VRS, patients may pressure clinicians for antibiotics, in addition
to symptomatic therapy, especially when nasal discharge is
colored or purulent. Existing educational material from the
Centers for Disease Control and Prevention (CDC) Get Smart
Campaign can be used by clinicians to help clarify misconcep-
tions about viral illness and nasal discharge.286

Anticipated barriers to “watchful waiting” for ABRS are
the reluctance of patients and clinicians to consider observing
a presumed bacterial illness. Compared with the first version
of this guideline,1 however, there is now a more robust evi-
dence base to substantiate watchful waiting as an initial man-
agement strategy, even when more severe symptoms are
present. These barriers can be overcome with an educational
handout (Table 6) of patient information of nonsevere ABRS,
the moderate incremental benefit of antibiotics on clinical out-
comes, and the potential adverse effects of orally administered
antibiotics (including induced bacterial resistance).

A potential barrier to using “wait-and-see” or “safety net”
prescriptions as part of a watchful waiting strategy for initial
management of ABRS is that electronic health records may
consider all antibiotic prescriptions, even if never filled by the
patient, as “antibiotic prescribing,” which could adversely
affect quality measures. One solution would be for companies
that produce electronic health records to include a means of
documenting delayed prescribing strategies (eg, wait-and-see)
for antibiotic therapy.

Some patients and clinicians might object to amoxicillin,
with or without clavulanate, as first-line therapy for ABRS,
based on assumptions that newer, more expensive alternatives
“must be” more effective. Most favorable clinical outcomes
for nonsevere ABRS, however, result from natural history, not
antibiotics, and randomized controlled trials of comparative
efficacy do not support superiority of any single agent for ini-
tial empiric therapy. Pamphlets may help in dispelling myths
about comparative efficacy.

Barriers may also be anticipated concerning guideline
statements for CRS and recurrent acute rhinosinusitis. The
diagnostic criteria for these entities are unfamiliar to many cli-
nicians, who might benefit from a summary card or teaching
aid that lists these criteria along with those for ABRS and
VRS. Performance of nasal endoscopy, allergy evaluation,
and immunologic assessment, when appropriate, may be hin-
dered by access to equipment and by procedural cost.

Research Needs
The guideline development group identified knowledge gaps
based on existing practice patterns and the scope and quality
of supporting literature. We present these gaps below to high-
light areas for future research and investigation.

1. Define the natural history and management of sub-
acute rhinosinusitis.
2. Determine the validity of diagnosing ABRS by
patient history without confirmatory physical
examination.
3. Refine and validate diagnostic criteria for VRS and
ABRS
4. Determine whether a 7- or 10-day symptom dura-
tion is more likely to be associated with ABRS.
5. Assess the validity of diagnosing ABRS before
10 days based on persistent fever plus concurrent
purulent nasal discharge.
6. Determine whether a diagnostic algorithm tool
would change physician behavior in terms of anti-
biotic prescription practices.
7. Assess the impact of clinician beliefs about anti-
biotic prescribing for ABRS and how they might
affect patient preferences and satisfaction.
8. Assess the value of viral screening methods in the rou-
tine management of patients with suspected ABRS.
9. Conduct randomized controlled trials (RCTs) to
determine the efficacy of an “observation option”
for nonsevere ABRS, by randomizing patients to
immediate vs delayed antibiotics and assessing
clinical outcomes.
10. Standardize the definition of “severe” illness in
patients diagnosed with ABRS and determine
whether it is a valid and useful distinction for diag-
osis in adults. Establish the proper terminology
and management of sinusitis symptoms lasting
between 4 and 12 weeks.
11. Conduct RCTs with a superiority design that
emphasize time to improvement/resolution, not just
binary outcomes at fixed time points.
12. Perform RCTs of antibiotics vs placebo using strict
diagnostic criteria and stratify by clinical severity
(ie, mild, moderate, or severe).
13. Perform RCTs to assess the comparative efficacy
of different antibiotics for initial management of
uncomplicated ABRS.
14. Evaluate the role of analgesic therapy in managing
rhinosinusitis and the comparative efficacy of dif-
ferent drug classes.
15. Assess the benefits of symptomatic therapy for
VRS in properly conducted RCTs.
16. Assess the benefits of various symptomatic thera-
pies for ABRS in properly conducted RCTs.
17. Determine optimum salinity, pH, and regimen for
administering nasal saline irrigation.
18. Devise strategies or treatment regimens to avoid
the rebound effect of topical nasal decongestants.
19. Determine the comparative clinical efficacy of anti-
biotics for culture-proven ABRS using RCTs with
standardized, uniform definitions of clinical dis-
ease, severity, and clinical outcomes.
20. Conduct RCTs to determine the efficacy of adju-
vant therapy (nasal steroids, antihistamines, decon-
gestants) in combination with antibiotics.
21. Obtain greater evidence for which ABRS patients are
most appropriate for short-course antibiotic regimens.
22. Perform RCTs examining antibiotic efficacy among
patient subpopulations and efficacy of fluoroquino-
lones relative to other antibiotics.
23. Include quality-of-life and other patient-reported outcome measures as study outcomes in RCTs.
25. Conduct investigations to further characterize the role of fungi in the etiology of inflammation of the paranasal sinuses.
26. Conduct investigations to determine the underlying causes of the inflammation that characterizes CRS and to determine the value of individualizing therapy based on this information.
27. Determine the pathogenesis of CRS and the association of allergic rhinitis and CRS.
28. Establish the benefit of testing for allergy and immune function in subgroups of patients with CRS.
29. Perform RCTs to address outcomes of allergy management in patients with CRS or recurrent acute rhinosinusitis.
30. Perform RCTs to address outcomes of detecting and managing immunodeficient states in patients with CRS or recurrent acute rhinosinusitis.
31. Validate nasal endoscopy scoring systems.
32. Assess the impact of intravenous immunoglobulin (IVIG) on CRS or recurrent acute rhinosinusitis in patients with humoral immune deficiency.
33. Conduct longitudinal studies with comparable control groups to evaluate long-term benefits of adjunctive therapies in the secondary prevention of CRS and recurrent acute rhinosinusitis.
34. Perform quantitative studies evaluating the impact of healthy lifestyle changes, such as smoking cessation, dietary modification, and exercise on CRS.
35. Conduct RCTs of saline nasal irrigations as short-term vs long-term treatment for recurrent acute and CRS.
36. Determine whether there is a difference in efficacy between isotonic and hypertonic concentrations for intranasal saline irrigations.
37. Define what is maximal medical therapy, including the efficacy of certain medications over others and the amount of time required for treatment.
38. Identify the natural history of CRS and determine whether it is curable.
39. Determine if certain subtypes of CRS with nasal polyps may respond to antifungal therapy.
41. Perform additional RCTs to clarify the impact of antibiotic therapy on CRS outcomes.

Acknowledgments

We gratefully acknowledge the support of Tiffany Moxham for her assistance with the literature searches. In addition, we acknowledge the work of the original guideline development group that includes David Andes, MD; Neil Bhattacharyya, MD; Dickson Cheung, MD, MBA; Steven Eisenberg, MD; Theodore G. Ganiats, MD; Andrea Gelzer, MD, MS; Daniel Hamilos, MD; Richard C. Haydon III, MD; Patricia A. Hudgins III, MD; Stacie Jones, MPH; Helene J. Krouse, PhD, APRN; Lawrence H. Lee, MD, MBA; Martin C. Mahoney, MD, PhD; Bradley F. Marple, MD; Col. John P. Mitchell, MC, MD; Robert Nathan, MD; Richard N. Shiffman, MD, MCI; Timothy L. Smith, MD, MPH; and David L. Witsell, MD, MHS.

Disclaimer

The clinical practice guideline is provided for information and educational purposes only. It is not intended as a sole source of guidance in managing adults with rhinosinusitis. Rather, it is designed to assist clinicians by providing an evidence-based framework for decision-making strategies. The guideline is not intended to replace clinical judgment or establish a protocol for all individuals with this condition and may not provide the only appropriate approach to diagnosing and managing this program of care. As medical knowledge expands and technology advances, clinical indicators and guidelines are promoted as conditional and provisional proposals of what is recommended under specific conditions but are not absolute. Guidelines are not mandates; these do not and should not purport to be a legal standard of care. The responsible physician, in light of all circumstances presented by the individual patient, must determine the appropriate treatment. Adherence to these guidelines will not ensure successful patient outcomes in every situation. The AAO-HNSF emphasizes that these clinical guidelines should not be deemed to include all proper treatment decisions or methods of care, or to exclude other treatment decisions or methods of care reasonably directed to obtaining the same results.

Author Contributions

Richard M. Rosenfeld, writer, chair; Jay F. Piccirillo, writer, assistant chair; Sujana S. Chandrasekhar, writer, methodologist; Itzhak Brook, writer, panel member; Kaparaboyna Ashok Kumar, writer, panel member; Maggie Kramper, writer, panel member; Richard R. Orlandi, writer, panel member; James N. Palmer, writer, panel member; Zara M. Patel, writer, panel member; Anju Peters, writer, panel member; Sandra A. Walsh, writer, panel member; Maureen D. Corrigan, writer, AAO-HNSF staff liaison.

Disclosures

Competing interests: Sujana S. Chandrasekhar, shareholder in Scientific Development and Research; Kaparaboyna Ashok Kumar, speaker for National Procedures Institute and consultant for Fetal Alcohol Spectrum of Disorders (CDC); Richard R. Orlandi, consulting fee from Medtronic; James N. Palmer, ownership of Pathway–HC Pathways; Zara M. Patel, Honorarium to teach–ENT-Arthrocare; Anju Peters, consulting fee from Baxter, advisory board for Greer Laboratories; Maureen D. Corrigan, salaried employee of AAO-HNSF.


Funding source: American Academy of Otolaryngology—Head and Neck Surgery Foundation.

References

2. Institute of Medicine, Committee on Standards for Developing Trustworthy Guidelines. **Clinical Practice Guidelines We Can Trust.** Washington, DC: National Academies Press; 2011.


39. Colla CH, Morden NE, Sequist TD, Schpero WL, Rosenthal MB. Choosing wisely: prevalence and correlates of low-value health
care services in the United States [published online November 6, 2014]. J Gen Intern Med.


141. Brook I, Gober AE. Antimicrobial resistance in the nasopharyngeal flora of children with acute maxillary sinusitis and...


